Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252422],  and degarelix  alone  for patients  with prostate  cancer  with a 
rising  PSA or a rising  PSA and nodal  disease  following  definitive  radical  prostatectomy  
 
PCCTC LOI  #: c11-092 
 
 
Lead  Site: Memorial  Sloan -Kettering  Cancer  Center  
 
Sponsor : Memorial  Sloan -Kettering  Cancer  Center  
 
 
 
Principal  Investigator  
[INVESTIGATOR_86223]  I. Scher, MD  
Service  Chief,  Genitourinary  Oncology  Service  
email:  [EMAIL_4095]  Statistician  
Glenn  Heller,  PhD 
Memorial Sloan -Kettering  Cancer Center  
email:  [EMAIL_4096]  
Co-investigator  
Michael  Morris,  MD 
Associate  Attending,  Genitourinary  Oncology  Service  
email:  [EMAIL_4097]  Protocol  Manager  
Ahkeem  Simmons  
Prostate  Cancer  Clinical Trials  Consortium  
email:  [EMAIL_4098]  
 
 
 
 
Participating  Sites  Principal  Investigator  [CONTACT_93529]’s  Role 
Oregon  Health  and Science  
University,  Knight  Cancer  Institute  Julie Graff,  MD Data Collection  
Rutgers  Cancer  Institute  of New 
Jersey  Tina Mayer,  MD Data Collection  
North  Shore  University  Health  
System  Daniel  Shevrin,  MD Data Collection  
Duke  University  Medical  Center  Michael  Harrison,  MD Data Collection  
Northwestern  University,  Feinberg  
School  of Medicine  Timothy  Kuzel, MD  Data Collection  
Johns  Hopkins  University,  The 
Sidney  Kimmel  Comprehensive  
Cancer Center   
Emmanuel  Antonarakis,  MD  
Data Collection  
University  of North  Carolina  Matthew  I. Milowsky,  MD Data Collection  
Karmanos  Cancer  Institute,  Wayne  Ulka  Vaishampayan,  MD Data Collection  

2 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252423],  MD Data Collection  
 
 
 
 
 
 
Protocol  Date:  August  8, 2012  
Amended  Version  Date:  October  22, 2012  
Amended  Version  Date:  December  27, 2013  
Amended  Version  Date:  August  11, 2014  
Amended  Version  Date:  August  12, [ADDRESS_252424]  study -related  activities.  

3 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
  
 
INVESTIGATOR’S  APPROVAL  OF PROTOCOL  
 
 
 
 
Title:  A phase  2, randomized,  3-arm study  of abiraterone  acetate  alone,  
abiraterone  acetate  plus degarelix,  a GnRH  antagonist,  and degarelix  
alone  for patients  with prostate  cancer  with a rising  PSA or a rising  
PSA and nodal  disease  following  definitive radical  prostatectomy  
 
 
 
 
 
 
 
 
Principal                                              Investigator                                              [INVESTIGATOR_7496]:   
  Principal  Investigator                                                                                                       
[INVESTIGATOR_43146]:     
Date:  

4 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252425],  and degarelix  alone  for patients  with 
prostate  cancer  with a rising  PSA or a rising  PSA and nodal  disease  following  
definitive  radical  prostatectomy  
Lead  site Memorial Sloan -Kettering  Cancer Center  
Sponsor  Memorial Sloan -Kettering  Cancer Center  
Investigational  agent  Abiraterone  acetate  (Janssen  Scientific  Affairs,  LLC)  1000  mg (four  250 mg 
tablets)  daily  plus prednisone  5 mg once  daily;  abiraterone  acetate  plus prednisone  
with once monthly  degarelix  injection  or; once monthly  degarelix  injection  only.  
Phase  Phase [ADDRESS_252426]-radical  prostatectomy  men with a serum  testosterone  of 150 ng/dL  or greater  
who now have a rising  PSA and a PSADT  ≤ 9 months  without  metastatic  disease.  
However,  patients  with pelvic  and/or  retroperitoneal  nodes  < [ADDRESS_252427] definitive  
metastases.  
Start  date/Duration  It is anticipated  that the trial will remain  open  to accrual  for [ADDRESS_252428] a rising  PSA and a PSADT  ≤ 9 months  without  
definitive  metastatic  disease.  The initial  screening  endpoint  to determine  whether  
the approach  is worthy  of further  study  is an undetectable  PSA with non-castrate  
levels  of testosterone  at 18 months  from  the time of  treatment  initiation  (PSA0).  
 
Androgen  depletion  and/or  blockade  currently  practiced  with degarelix,  a GnRH  
agonist/antagonist  with or without  an antiandrogen  produces  declines  in PSA 
followed  by [CONTACT_211120],  a period of quiescence  during which  the disease  does 
not proliferate,  followed  by a rise in PSA and regrowth  as a castration -resistant  
prostate  cancer  (CRPC)  that for most  men is invariably lethal.  Androgen  depletion  
as traditionally  utilized  does not completely  inhibit  androgen  responsive  gene 
expression  (PSA,  etc.),1 it does not consistently  produce  levels  of testosterone  
below  20 ng/dL,2-[ADDRESS_252429]  and/or  survive  in a low androgen  environment  when  the 
disease  is first manifest  clinically .5 Overall  outcomes  with ADT  are inversely  
related  to disease  burden  and the results  of multiple  series  show  that patients  with 
5 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 
 
more  advanced  disease  progress  and die sooner  in comparison  to those  with less 
advanced  disea se.6,7 Even  in the neoadjuvant  setting  where  the disease  is clinically  
confined  to the gland,  prostates  removed  after 3 months  or up to 8 months  of 
treatment  are rarely  tumor -free.8 
We hypothesize  that abiraterone -based  treatments  will be superior  to androgen  
depletion  with degarelix  alone,  and potentially  cure (primary  endpoint:  
progression -free survival  at 18 months  from  the time of randomization)  a 
proportion  of men with a rising  PSA and a rapid  PSADT  without  definitive  
metastatic  disease  following  radical  prostatectomy.  The potential  clinical  benefit  of 
the approach  under  study  includes  the potential  for cure,  as well as the avoidance  
of repeated  cycles  of hormone  therapy  treatment,  each of which  is associated  with 
short  term and long  term toxicities,  some  of which  are cumulative.  
The study  is focused  on men with a rising  PSA and rapid  PSADTs  without  
definitive  metastatic  disease  who are at risk for prostate  cancer -specific  morbidity  
and mortality .9-[ADDRESS_252430]  probability  of demonstrating   clinical  
benefit  in a short  time frame.  Three  treatment  groups  will be studied:  abiraterone  
acetate  alone,  abiraterone  acetate  plus degarelix,  and degarelix  alone.  We have 
selected  degarelix  to avoid  the initial  serum  testosterone  elevations  that occur  with 
GnRH  agonists/antagonists  which  are not completely  blocked  with the currently  
available  anti-androg ens.3,17 Degarelix  treatment  reduces  serum  androgen  levels  to 
a castrate  range  within 48 hours.18 
Study design  A randomized  phase  2 screening  design  is used to compare  the efficacy  of 
abiraterone  acetate  and abiraterone  acetate  plus degarelix  to degarelix  alone  for 
prostate  cancer  patients  in the rising  PSA clinical  state.  
 
After  obtaining  informed  consent,  patients  who satisfy  the eligibility  requirements  
will be randomized  prospectively:  
 
Arm  1 
• Abiraterone  acetate  1000  mg daily  x 8 months  
• Prednisone  5 mg once daily  x 8 months  
 
Arm  2 
• Abiraterone  acetate  1000  mg daily  x 8 months  
• Prednisone  5 mg once daily  x 8 months  
• Degarelix  subcutaneous  depot  injection(s) q 1 month  x 8 months  
 
Arm  3 
• Degarelix  subcutaneous  depot  injection(s) q 1 month  x 8 months  
Criteria  for Primary  endpoint:  
The primary  endpoint  for each cohort  is progression -free survival  (PFS)  at 18 
6 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 
 
evaluation  months  from  the start of treatment  initiation  (PSA0).  PFS is defined  as an 
undetectable  PSA (at the institution  of participant  registration)  with a non-castrate  
level  of testosterone  (>150  ng/dL).  Pathological  lymph  nodes  (whether  target  or 
non‐target)  must  also have reduction  in short  axis to <10 mm (Complete  Response  
per RECIST)  in order  to meet  the criteria  for PFS.  
 
Secondary  endpoints : 
• PSA response  rate (Percentage  of patients  with an undetectable  PSA at 8 months  
from  PSA0).  
• Effects  of each arm on overall  quality  of life, with particular  attention  to libido,  
potency,  anxiety,  depression,  hot flashes,  and fatigue.  
• Frequency  and intensity  of non-hematologic  adverse  events.  
• Testosterone  and leuteinizing  hormone  (LH)  recovery  rates.  
Tertiary  endpoint:  
• Correlative  tissue  analysis  with clinical  outcomes  while  on study  treatment.  
Statistical  method  One hundred  and twenty patients  will be randomized  to the three  treatment  groups.  
Each  abiraterone  acetate  group  will be compared  to the degarelix  alone  group.  
With  40 patients  per group,  it is assumed  that the probability  of a success  in the 
degarelix  alone  group  is ≤ 0.[ADDRESS_252431] 0.20 
greater  than degarelix  alone  in the abiraterone  acetate -based  groups.  Under  these  
projections,  there  is greater  than an 80% chance  of finding  for either  abiraterone  
acetate -based  treatment  relative  to degarelix  alone  using  Fisher’s  exact  test with a 
one-sided  0.20 significance  level.  
 
The choice  of a 0.20 significance  level  is intended to reduce  the sample  size required  
for this comparative  study.  A significant  outcome  does not imply  definitive  evidence  
of superiority  for either  abiraterone  acetate -based  treatment  relative  to degarelix  
alone  due to this high type 1 error,  but instead  provides  sufficient  evidence  that 
testing  of abiraterone  acetate  should  proceed  to a large -scale  randomized  phase  3 
study  in this patient  population.  
Safety  analysis  Safety  analysis  will be summarized  using  the Safety  Population  defined  as any 
patient  receiving  any part of study  treatment.  
 
Extent  of exposure  to study  treatment  will be summarized  and details  will be 
provided.  Treatment  emergent  adverse  events  (AEs)  are those  events  that occur  or 
worsen  on or after first dose of study  drug up through  [ADDRESS_252432]  current  National  Cancer  Institute  Common  
Terminology  Criteria  for Adverse  Events  (CTCAE).  
7 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 
 
TABLE OF  CONTENTS  
1. INTRODUCTION  ................................ ................................ ................................ ................................ ...........................  9 
1.1 Disease Background ................................ ................................ ................................ ................................ ................................ 9 
1.2 Rising  PSA Clinical  State  ................................ ................................ ................................ ................................ ..................... 9 
1.3 Androgen  Depletion  and/or Blockade  for PSA Progression  ................................ ................................ ..................  10 
1.4 Abiraterone  Acetate ................................ ................................ ................................ ................................ ..............................  11 
1.5 Clinical Benefits  of Proposed  Treatment  ................................ ................................ ................................ ......................  18 
1.6 Rationale  for Therapeutic Intervention  ................................ ................................ ................................ .........................  18 
1.7 Choice of Undetectable  PSA as the Primary  Endpoint  ................................ ................................ ............................  18 
2. OBJECTIVES  ................................ ................................ ................................ ................................ ...............................  19 
2.1 Primary  Objective  ................................ ................................ ................................ ................................ ................................ . 19 
2.2 Secondary  Objectives  ................................ ................................ ................................ ................................ ..........................  19 
3. PATIENT  SELECTION  ................................ ................................ ................................ ................................ .............  19 
3.1 Target  Population  ................................ ................................ ................................ ................................ ................................ .. 19 
3.2 Inclusion  Criteria  ................................ ................................ ................................ ................................ ................................ ... 19 
3.3 Exclusion  Crite ria ................................ ................................ ................................ ................................ ................................ . 20 
4. PATIENT  REGISTRATION  ................................ ................................ ................................ ................................ ..... 22 
4.1 Lead  Center  (MSKCC) Registration  ................................ ................................ ................................ ..............................  [ADDRESS_252433]-Treatment  Follow -Up ................................ ................................ ...................  28 
6. STUDY PROCEDURES  ................................ ................................ ................................ ................................ .............  28 
6.1 Informed  Consent ................................ ................................ ................................ ................................ ................................ .. 31 
6.2 Medical  History  ................................ ................................ ................................ ................................ ................................ ..... 31 
6.3 Physical Examination  ................................ ................................ ................................ ................................ ..........................  31 
6.4 Cardiac  Function  ................................ ................................ ................................ ................................ ................................ ... 31 
6.5 Clinical laboratory  Tests  ................................ ................................ ................................ ................................ .....................  32 
6.6 Efficacy/Response  Assessments  ................................ ................................ ................................ ................................ ...... 32 
6.7 Testosterone  and Luteinizing  Hormone Recovery  Rates  ................................ ................................ ........................  32 
6.8 Patient -reported Outcomes  ................................ ................................ ................................ ................................ ................  32 
6.9 Safety  Evaluation  ................................ ................................ ................................ ................................ ................................ .. 33 
6.10 Correlative Studies  ................................ ................................ ................................ ................................ ...............................  33 
7. STUDY  ACTIVITIES  ................................ ................................ ................................ ................................ .................  33 
7.1 Within  30 Days  Prior to  Protocol Therapy  Initiation  ................................ ................................ ................................  33 
7.2 Within  14 Days  Prior to  Protocol Therapy  Initiation  ................................ ................................ ................................  34 
7.3 Treatment  Period  (Day  1 ±3 days to Week  32 ± 3 days)  ................................ ................................ .........................  [ADDRESS_252434]-treatment  Follow -up ................................ ................................ ................................ ................................ ...................  36 
8. ADVERSE EVENTS  ................................ ................................ ................................ ................................ ...................  36 
8.1 Definitions  ................................ ................................ ................................ ................................ ................................ ...............  36 
8.2 Management  of Adverse  Events,  Serious Adverse  Events  and Special  Reporting  Situations  ....................  38 
8.3 Recording  of Adverse  Events,  Serious  Adverse  Events  and Special  Reporting  Situations  .........................  38 
8.4 Grading  Adverse  Events  ................................ ................................ ................................ ................................ .....................  39 
8 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 9. TREATMENT  EVALUATION  AND  OUTCOMES  ................................ ................................ ............................  44 
9.1 Primary  Endpoint  ................................ ................................ ................................ ................................ ................................ .. 44 
9.2 Secondary  Endpoints  ................................ ................................ ................................ ................................ ...........................  45 
9.3 Tertiary  Endpoint  ................................ ................................ ................................ ................................ ................................ .. 45 
10. DATA  REPORTING  AND  REGULATORY  REQUIREMENTS  ................................ ................................ .... 45 
10.1 Data  Collection  and Management  ................................ ................................ ................................ ................................ .... 45 
10.2   Study  Monitoring  and Quality  Assurance  ................................ ................................ ................................ .....................  46 
11. STATISTICAL  METHODS  ................................ ................................ ................................ ................................ ....... 48 
11.1 General  Considerations  ................................ ................................ ................................ ................................ .......................  48 
11.2 Sample  Size Determination ................................ ................................ ................................ ................................ ................  48 
11.3 Analysis  Population ................................ ................................ ................................ ................................ ..............................  48 
11.4 Demographics  and Baseline  Characteristics  ................................ ................................ ................................ .................  49 
11.5 Safety  Analysis  ................................ ................................ ................................ ................................ ................................ ...... 49 
12. REGULATORY  AND  PROTECTION  OF HUMAN  SUBJECTS  ................................ ................................ ... 49 
12.1 Roles  and Responsibilities  ................................ ................................ ................................ ................................ ...............  49 
12.2   Ethical  Considerations  ................................ ................................ ................................ ................................ .........................  50 
12.3   Regulatory  Documentation  ................................ ................................ ................................ ................................ ..............  50 
12.4   Protocol  Amendments  ................................ ................................ ................................ ................................ ..........................  51 
12.6 Written  Informed  Consent  ................................ ................................ ................................ ................................ ..................  52 
12.7 Protection  of Privacy  ................................ ................................ ................................ ................................ ............................  52 
12.8 Terminating  or Modifying  the Study  ................................ ................................ ................................ ..............................  52 
13. REFERENCES  ................................ ................................ ................................ ................................ ................................ ........  53 
APPENDIX  A: ECOG  PERFORMANCE  STATUS  SCALE  ................................ ................................ ........................  56 
APPENDIX  B: PRO  SURVEY  ................................ ................................ ................................ ................................ ..............  57 
APPENDIX  C: JANSSEN  SERIOUS  ADVERSE  EVENT  REPORT  FORM  (FOR  PCCTC)  ..............................  61 
APPENDIX  D: PCCTC  SAE  REPORT  FORM  FOR  ALL  SITES  ................................ ................................ ..............  65 
APPENDIX  E: GLOSSARY  OF ABBREVIATIONS  AND  ACRONYMS  ................................ ................................  66 
9 of 69 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 
 
1. INTRODUCTION  
1.1 Disease  Background  
The course  of prostate  cancer  from  diagnosis  to death  can be categorized  as a series  of clinical  
states  (Figure  1) based  on the status  of the primary  tumor,  presence  or absence  of visible  
metastatic  disease  on an imaging  study,  and the measured  level  of testosterone  in the blood.19 The 
states  are localized  disease,  rising  levels  of prostate -specific  antigen  (PSA)  after radiation  therapy  
or surgery  with no detectable  metastases,  and clinical  metastases  in the non-castrate  or castrate  
state.  
Figure  1. Clinical  states  of prostate  cancer  
 
 
 
 
 
Clinically  
Localized  
Disease  2 
Clinical  
Metastases:  
 
Pre- 
Provenge  
Abiraterone   
3 
Clinical  
Metastases:  
Castrate  
1st Line 
Docetaxel  
 
 
Neoadjuvant  
Adjuvant  
 
1.[ADDRESS_252435] by a 
rising  level  of PSA.  For these  individuals,  the issue  is to determine  whether  the disease  is local  or 
systemic,  and if the later,  the risk of developi[INVESTIGATOR_211086]  – a transition  to the lethal  
phenotype  of the illness  and in what  time frame.   A number  of nomograms  based  on the  
characteristics  of the primary  tumor,  time to a detectable  PSA following  surgery,  and rate of rise 
in PSA or PSA doubling  time (PSADT)  have been developed  to estimate  prognosis,  which  for the 
group as a whole  is heterogeneous .20-24 
In one series  of patients  with rising  PSA enrolled  on clinical  protocols  (N = 148) PSADT  was a 
statistically  significant  independent  predictor  for metastatic  progression  (P = 0.001 ).[ADDRESS_252436]  men with a PSADT  of 12 months  or less are treated,  but we are restricting  
eligibility  to men with a PSADT  of 9 months  or less based  on the recently  reported  metastases  
free survival  times  in a contemporary  series  (Table  1). 
Table  1. Metastasis -free survival  (MFS)  after  PSA recurrence  according  to PSADT    
 PSADT  < 3 mos 
(N = 46) PSADT  3-9 mos 
(N = 106) PSADT  9-15 mos 
(N = 86) PSADT  ≥ 15 mos 
(N = 212) 
Median  MFS,  years  
(95%  CI) 1 (0,1)  4 (2,4)  13 (6, >15)  15 (15, >17)  
Metastasis -free rate at 
5 years,  % (95%  CI) 5 (1, 21)* 27 (16, 39) 77 (63, 86) 91 (85, 95) 
Metastasis -free rate at 
10 years,  % (95%  CI) N/A 7 (1, 22) 51 (34, 66) 72 (59, 83) 
*Last  subject censored  at 4 years.  In each subgroup,  the median  MFS  as well as the 5- and 10-year probabilities of  
MFS from  the time of PSA recurrence are shown.  N/A,  not applicable.  Clinical  
Metastases:  
Non-Castrate  4 
Clinical  
Metastases:  
 
Post - 
Cabazitaxel  
Abiraterone   
Rising  
PSA 1 
Rising  PSA:  
Castrate  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
10 of 69  
 In this series,  73% of men with a  PSADT in the range  of 3-9 months,  and 95% of men with a  
PSADT  of less than 3 months  developed  visible  metastatic  disease  at 5 years.  
 
We are also including  men with visible  pelvic  and/or  retroperitoneal  nodes  < 2 cm in short  axis, 
as nodal  disease  at this site of spread  is particularly  sensitive  to and will often  completely  regress  
on androgen  depletion  therapy,  and will not recur  at the time of relapse.  
 
1.3 Androgen  Depletion  and/or  Blockade  for PSA  Progression  
Androgen  depletion  and/or  blockade  (ADT)  as currently  practiced  with a gonadotropin -releasing  
hormone  (GnRH)  agonist/antagonist  with or without  an antiandrogen  produces  declines  in PSA 
followed  by [CONTACT_211120],  a period  of quiescence  during  which  the disease  does not 
proliferate,  followed  by a rise in PSA and regrowth  as a castration -resistant  prostate  cancer  
(CRPC)  that for most  men is invariably  lethal.  Overall  outcomes  are inversely  related  to disease  
burden  and the results  of multiple  series  show that patients  with more advanced  disease  progress 
sooner in comparison  to those with  less advanced  disease.6,7 
We hypothesize  that abiraterone -based  treatments  will be superior  to androgen  depletion  with 
degarelix  alone,  and potentially  cure (primary  endpoint:  progression -free survival  at 18 months  
from  the time of randomization)  a proportion  of men with a rising PSA  and a PSADT  ≤ 9 months  
without  definitive  metastatic  disease  following  radical  prostatectomy.  
 
1.3.1  ADT  does not completely  suppress  androgen  signaling  
Androgen  depletion  as traditionally  utilized  does not completely  inhibit  androgen  
responsive gene  expression  (PSA,  etc.),1 it does not consistently  produce  levels  of 
testosterone below 20 ng/dl ,2-[ADDRESS_252437]  and/or  survive  in a low androgen  environment  when  the 
disease  is first manifest  clinically .[ADDRESS_252438]-hormone  
treated  primary  tumors,  and castration  resistant  metastatic  disease.  In pre-prostatectomy  
hormone  treated  patients,  we found  that androgen  receptor  (AR)  gene expression  in the 
residual  tumor  in the prostate  after [ADDRESS_252439]-hormone  treated  samples  continued  to express  AR target  genes  such as 
PSA,  prostatic  acid phosphatase,  prostate  specific  transglutaminase  (TGP),  KLK1,  and 
TMPRSS2.1 An association  was shown  between  the level  of PSA mRNA  and protein  
expression and  biochemical  relapse.28 The finding  that intratumoral  androgen  levels  are 
only reduced  by 75% following  conventional  ADT,  at the time when  androgen  levels  in 
the blood  are in the castrate  range,[ADDRESS_252440] demonstrated  
increased  intratumoral  androgens  in the prostates  of men who had  undergone  castration,30 
a finding  confirmed  by [CONTACT_2312].  Adrenal  androgen  synthesis  was the postulated  source,  
although a failure  to completely  suppress  androgen production  could  not be excluded.29,31- 
33 Subsequently,  Holzbeierlein  et al1 reported  an up to 5-fold induction  of several enzymes  
involved in steroid hormone  production,  also confirmed  by [CONTACT_2312],34,35                         
suggesting  the possibility  of intratumoral production  of androgens  as the primary  source.  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252441]  explored  the approach  with “on cycles”  of varied  duration,  
but in most  studies,  the maximal  response  is observed  by [ADDRESS_252442] selected  for the current  study .40 
1.3.3  Time to  testosterone  recovery  
The incidence  of, and length  of time to recovery  tends  to decline  with subsequent  off- 
treatment  cycles  and is a function  of longer  treatment  schedules,  lower  pretreatment  
baseline PSA testosterone  levels,  and advancing  age.41 Overall,  testosterone  levels  return  
to a non-castrate  range with 6 months  of stoppi[INVESTIGATOR_211087] 75% of cases  (Figure  2). 
 
 
Figure  2. Recovery  of testicular  function  after androgen  suppression.  
The proportion  of patients  with serum  testosterone  levels  ≥7.5 nmol/l  is plotted  as a function  of time 
after the interruption  of androgen  withdrawal  therapy.  These  results  show  that testosterone  recovery  
occurs  in many  patients,  especially  in the first off-treatment  phase.41 
 
1.4 Abiraterone  Acetate  
Abiraterone  acetate  is a steroidal  inhibitor  of CYP17  that blocks  two important  enzymatic  
activities  in the synthesis  of testosterone.  It was developed  originally  for use in the non-castrate  
hormone  naïve  (non-castrate)  setting,  an indication  that was  largely  abandoned  after an initial  
proof  of concept  trial. Of particular  interest  was the demonstration  that abiraterone  acetate  
treatment  resulted  in testosterone  levels  to the 1-2 ng/dL  range  which  is significantly  lower  than 
the20 -30 ng/dL  range  achieved  with conventional  androge n-depletion  with a surgical  
orchiectomy  or GnRH agonist/antagonist  with or without  an antiandrogen.[ADDRESS_252443] received  prior  chemotherapy  
containing  docetaxel.  In December  2012,  the FDA  approved  abiraterone  acetate  for use in 

12 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252444] not yet  
 received  chemotherapy.  
 
1.4.1 Description  and mechanism of action  
Pharmacology  
Abiraterone  acetate  is converted  in vivo to abiraterone,  an androgen  biosynthesis  
inhibitor,  that inhibits  17 α-hydroxylase/C17,  20-lyase  (CYP17).  This enzyme  is 
expressed  in testicular,  adrenal,  and prostatic  tumor  tissues  and is required  for androgen  
biosynthesis.  
 
CYP17  catalyzes  two sequential  reactions:  1) the conversion  of pregnenolone  and 
progesterone  to their 17α-hydroxy  deriv atives  by 17α-hydroxylase  activity  and 2) the 
subsequent  formation  of dehydroepi[INVESTIGATOR_2119]  (DHEA)  and androstenedione,  
respectively,  by C17,  [ADDRESS_252445]  been  studied  in healthy  subjects  and in patients  with metastatic  
CRPC.  In vivo, abiraterone  acetate  is converted  to abiraterone.  In clinical  studies,  
abiraterone  acetate plasma  concentrations  were  below  detectable  levels  (< 0.2 ng/mL)  in 
> 99%  of the analyzed  samples.  
 
Following  oral administration  of abiraterone  acetate  to patients  with metastatic  CRPC,  
the median  time to reach  maximum  plasma  abiraterone  concentrations  is 2 hours.  
Abiraterone  accumulation  is observed  at steady -state,  with a 2-fold higher  exposure  
(steady -state AUC)  compared  to a single  1000  mg dose of abiraterone  acetate.  
 
At the dose of 1000  mg daily  in patients  with metastatic  CRPC,  steady -state values  (mean  
± SD) of Cmax were  232 ± 177 ng/mL  and of AUC  were  1060  ± 681 ng.hr/mL.  No major  
deviation  from  dose proportionality  was observed  in the dose range  of 250 mg to 1000  
mg. 
 
Systemic  exposure  of abiraterone  is increa sed when  abiraterone  acetate  is administered  
with food. Abiraterone  Cmax and AUC 0-∞ were  approximately  7- and 5-fold higher,  
respectively,  when  abiraterone  acetate  was administered  with a low-fat meal  (7% fat, 300 
calories)  and approximately  17- and 10-fold higher,  respectively,  when  abiraterone  
acetate  was administered  with a high-fat (57%  fat, 825 calories)  meal.  
 
1.4.2 Warnings  and precautions  
Hypertension,  Hypokalemia  and Fluid  Retention  Due to Mineralocorticoid  Excess  
Use abiraterone  acetate  with caution  in patients  with a history  of cardiovascular  disease.  
Abiraterone  acetate  may cause hypertension,  hypokalemia,  and fluid retention  as a 
consequence  of increased  mineralocorticoid  levels  resulting  from  CYP17  inhibition  [see 
Adverse  Reactions  (1.4.3)  and Description  of Mechanisms  of Action  (1.4.1)] . Co- 
administration  of a corticosteroid  suppresses  adrenocorticotropic  hormone  (ACTH)  drive,  
resulting  in a reduction  in the incidence  and severity  of these  adverse  reactions.  Use 
caution  when  treating  patients  whose  underlying  medical  conditions  might  be 
compromised  by [CONTACT_211121],  hypokalemia  or fluid retention,  e.g., those  
with heart  failure,  recent  myocardial  infarction  or ventricular  arrhythmia.  The safety  of 
13 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 abiraterone  acetate  in patients  with left ventricular  ejection  fraction  <50%  or NYHA   
Class  III or IV heart  failure  has not been established  because  these  patients  were  excluded  
from  the randomized  clinical  trial. Monitor  patients  for hypertension,  hypokalemia,  and 
fluid retention  at least once a month.  Control  hypertension  and correct  hypokalemia  
before  and during  treatment  with abiraterone  acetate.  
 
Adrenocortical  Insufficiency  
Adrenocortical  insufficiency  has been  reported  in clinical  trials  in patients  receiving  
abiraterone  acetate in combinati on with prednisone,  following  interruption  of daily  
steroids  and/or  with concurrent infection  or stress.  Use caution  and monitor  for symptoms  
and signs  of adrenocortical  insufficiency,  particularly  if patients  are withdrawn  from  
prednisone,  have prednisone  dose reductions,  or experience  unusual  stress.  Symptoms  and 
signs  of adrenocortical  insufficiency  may be masked  by [CONTACT_211122].  If 
clinically  indicated,  perform  appropriate  tests to confirm  the diagnosis  of adrenocortical  
insufficiency.  Increased  dosage  of corticosteroids  may be indicated  before,  during  and 
after stressful  situations  [see Warnings  and Precautions  (1.4.2)].  
 
Hepatotoxi city 
Marked  increases  in liver enzymes  leading  to drug discontinuation  or dosage  
modification  have occurred  [see Adverse  Reactions  (1.4.2)] . Measure  serum  
transaminases  (ALT and AST)  and bilirubin  levels  prior  to starting  treatment  with 
abiraterone  acetate,  every  two weeks  for the first three  months  of treatment  and monthly  
thereafter.  In patients  with baseline  moderate  hepatic  impairment  receiving  a reduced  
abiraterone  acetate dose of [ADDRESS_252446],  ALT,  or bilirubin  from  the patient's  baseline  should  prompt  more  frequent  
monitoring.  If at any time AST  or ALT  rise above  five times  the ULN,  or the bilirubin  
rises above  three  times  the ULN,  interrupt  abirateron e acetate  treatment  and closely  
monitor  liver function.  
 
Re-treatment  with abiraterone  acetate at a reduced  dose level  may take place  only after 
return  of liver function tests to the patient’s  baseline  or to AST and ALT  less than or 
equal  to 2.5X  ULN  and total bilirubin  less than or equal  to 1.5X  ULN  [see Study  
Treatments  (5)]. 
 
The safety  of abiraterone  acetate re -treatment  of patients  who develop  AST or ALT  
greater  than or equal  to 20X ULN  and/or  bilirubin  greater  than or equal  to 10X ULN is 
unknown.  
 
Food Effect  
Abiraterone  acetate  must  be taken  on an empty  stomach.  No food should  be consumed  
for at least two  hours  before  the dose of abiraterone  acetate is taken  and for at least one 
hour after the dose of abiraterone  acetate  is taken.  Abiraterone  Cmax and AUC 0-∞ 
(exposure)  were  increased  up to 17- and 10-fold higher,  respectively,  when  a single  dose 
of abiraterone  acetate  was administered  with a meal  compared  to a fasted  state.  The 
safety  of these  increased  exposures  when  multiple  doses  of abiraterone  acetate  are taken  
with food has not been assessed  [see Study  Treatments  (5) and Mechanism  of Action  
(1.4.1)].  
14 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252447]  the rates observed  in clinical  practice.  
 
In a placebo -controlled,  multicenter  phase  3 clinical  trial of patients  with metastatic  
castration -resistant  prostate  cancer  who were  using  a gonadotropin -releasing  hormone  
(GnRH)  agonist  or were  previously  treated  with orchiectomy,  but had no prior  
chemotherapy  (COU -AA-302),  abiraterone  acetate  was administered  at a dose of 1,000  
mg daily  in combination  with prednisone  5 mg twice  daily  in the active  treatment  arm (N 
= 546).  Placebo  plus prednisone  5 mg twice  daily  was given  to control  patients  (N = 
542).  The median  duration  of treatment  with abiraterone  acetate  was 13.[ADDRESS_252448]  common  adverse  drug reactions  (≥10% of subjects  in any  treatment  group)  
reported  in two large,  randomized,  double -blind,  placebo -controlled  Phase  3 abiraterone  
acetate  studies  (COU -AA-301 and COU -AA-302) were  fatigue  (44%),  back pain (33%),  
nausea  (28%),  arthralgia  (30%),  constipation  (26%),  bone  pain (24%),  peripheral  edema  
(26%),  hot flush  (21%),  and diarrhea  (21%).  Most  events  were  of Grade  [ADDRESS_252449] infection,  
hypertension,  and increased  alanine  aminotransferase  (ALT),  all of which  were  reported  
at higher  rates in COU -AA-[ADDRESS_252450] commonly  reported  AE leading  to treatment  
discontinuation  (1.7%  of subjects  in the abiraterone  acetate  group  and 0.2%  of subjects  in 
the placebo  group).  
 
Adverse  events  of special  interest  with abiraterone  acetate  therapy  include  fluid 
retention/edema,  hypokalemia,  hypertension,  cardiac  disorders,  and hepatotoxicity.  AEs 
of special  interest  were  reported  more  commonly  in patients treated  with abiraterone  
acetate  (61%  of combined  subjects  in phase  3 trials)  than in patients  treated  with placebo  
(48%).  Events  of hypokalemia  were reported  in 18% of subjects  in the abiraterone  acetate  
group  versus  9% of subjects  in the placebo  group  for study  COU -AA-301; for study  
COU -AA-302, these  proportions  were  17% and 13%,  respectively  (see Table  2). 
 
In patients  treated  with abiraterone  acetate,  grades  3 to 4 hypokalemia  occurred  in 5% of 
patients  in the COU -AA-301 study  and 3% of patients  in the COU -AA-302 study.  Grades  
3 to 4 hypertension  was reported  in 1% of patients  in COU -AA-301 and 4%  of patients  in 
COU -AA-302 [see Warnings  and Precautions  (1.4.2)] . 
 
Table  2 shows  adverse  reactions  due to abiraterone  acetate  that occurred  with either  a ≥ 
1% absolute  increase  in frequency  compared  to placebo,  or were  events  of special interest  
(mineralocorticoid  excess,  cardiac  adverse  reactions,  and liver toxicities).  
15 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 
 
 
Table  2. Adverse  reactions  due to  abiraterone  acetate  in a placebo -controlled  phase  3 trial  
Abiraterone  acetate  
with  Prednisone  
(N=791)   
Placebo  with  Prednisone  
(N=394)  
 
System/Organ  Class  
 
Adverse  reaction  All Grades1 
 
%  
Grade  3-4 
 
%  
All Grades  
 
%  
Grade  3-4 
 
% 
 
 
Musculoskeletal  and connective  tissue  disorders  
 
Joint  swelling/discomfort2 29.[ADDRESS_252451]  discomfort7 3.8 0.5 2.8 0 
16 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252452] pain,  and Angina  unstable.  Myocardial infarction or ischemia  occurred  more commonly  in the 
placebo arm  than in the ZYTIGA  arm (1.3%  vs. 1.1%  respectively).  
 
[ADDRESS_252453] elevations  (ALT  or AST increases  of > 5X ULN)  were  reported  in 2.3%  of 
patients  who received  abiraterone  acetate,  typi[INVESTIGATOR_211088] [ADDRESS_252454] > 5X ULN,  or elevations  in bilirubin  > 3X  
ULN  were  observed,  abiraterone  acetate  was withheld  or discontinued.  In two instances  
marked  increases  in liver function  tests occurred  [see Warnings  and Precautions    
(1.4.2 )]. These  two patients  with normal  baseline  hepatic  function,  experienced           
ALT  or AST elevations  [ADDRESS_252455].  Upon  discontinuation  of abiraterone  acetate,  both patients  had normalization  of 
their liver function  tests and one patient  was re-treated  with abiraterone  acetate  without  
recurrence  of the elevations.  
 
In clinical  trials,  the following  patients  were  excluded:  patients  with active  hepatitis,  
patients  with baseline  ALT  and/or  AST ≥ 2.5X  ULN  in the absence  of liver metastases,  
and patients  with ALT  and/or  AST > 5X ULN  in the presence  of liver metastases.  
Abnormal  liver function  tests developi[INVESTIGATOR_211089],  dose modification  and/or  discontinuation  [see Study  

17 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 Treatments  (5) and Warnings  and Precautions  (1.4.2)] . Patients  with elevations  of ALT  
or AST > 20X ULN  were  not re-treated.  
 
Other  Adverse  Reactions  
Adrenal  insufficiency  occurred  in two patients  on the abiraterone  acetate  arm of the phase  
3 clinical  trial (< 1%).  
 
Laboratory  Abnormalities  of Interest  
Table  [ADDRESS_252456]  from  the phase  3 placebo -controlled  
clinical  trial. Grade  3-4 low serum  phosphate  (7.2%)  and potassium  (5.3%)  occurred  
more frequently  in the  abiraterone  acetate  arm. 
 
Table 3. Laboratory  abnormalities  of interest  in a phase  3 placebo -controlled  clinical  trial 
Abiraterone  (N=791)  Placebo  (N=394)  
 
 
 
Laboratory  Abnormality  All Grades  
 
% Grade  3-4 
 
% All Grades  
 
% Grade  3-4 
 
% 
High  Triglyceride  62.[ADDRESS_252457]-chemotherapy  (Cougar -AA-301) setting,  which  
showed  a significant survival  benefit ,45 and pre-chemotherapy  (Cougar -AA-302),  which  
showed an  improvement  in radiographic  progression -free survival  and a  trend  toward  
improved overall  survival.53 
1.4.5 Development  of abiraterone  in non-castrate  disease  
 
A proof  of concept  phase  1 trial conducted  at the Royal Marsden  showed  that a dose of 
800 mg daily  produced  testosterone  levels  of 0.77 nmol/l  which,  in one patient,  was not 
sustained due  an increase  in luteinizing  hormone  (LH)  levels.[ADDRESS_252458]/antagonist increases  
response  in the primary  tumor  
Based  on these  findings,  Investigators  at the Dana -Farber  Cancer  Institute  and the Fred 
Hutchinson  Cancer  Center  are conducting  a prospective  trial in which  patients  receive  
either  Lupron  (leuprolide  acetate)  alone  or Lupron  plus abiraterone  acetate  plus 

18 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252459] been high risk 
and dramatic  antitumor  responses  seen,  which  suggests  that the additional  1 log reduction  
in androgen  levels  by [CONTACT_211123] (personal  
communication,  M. Taplin).  
 
1.5 Clinical  Benefits  of Proposed  Treatment  
The potential  clinical  benefit  of the approach  under  study  includes  the potential  for cure,  as well 
as the avoidance  of repeated  cycles  of hormone  therapy  treatment,  each of which  is associated  
with short  term and long  term toxicities,  some  of which  are cumulative.  We are focused  on men 
with a rising  PSA and a PSADT  ≤ 9 months  without  definitive  metastatic  disease,  who are at risk 
for prostate  cancer -specific  mortality .9-11 Patients with  pelvic  and/or  retroperitoneal  nodes < [ADDRESS_252460] our hypothesis  we will evaluated  three  treatment  groups:  abiraterone  
acetate  alone,  abiraterone  acetate  plus degarelix,  and degarelix  alone.  We have selected  degarelix  
to avoid  the initial  serum  testosterone  elevations  that occur  with GnRH agonists/antagonists  
which are  not completely  blocked with the currently  available anti -androg ens.3,17 Degarelix  
treatment  reduces  serum  androgen  levels  to a castrate  range within  48 hours.18 
1.7 Choice  of Undetectable  PSA as the  Primary  Endpoint  
Survival  is recognized  as a “gold  standard”  primary  endpoint  in clinical  trials.  As is the case for 
the treatment  of the primary  tumor,  we postulate  that disease  eradication  as evidenced by  [CONTACT_211124] a clinically  meaningful  therapeutic  objective  for men with a  rising  PSA and a  
PSADT  ≤ 9 months  without  definitive  metastatic  disease.  Patients  with pelvic  and/or  
retroperitoneal  nodes  < [ADDRESS_252461] definitive  metastases.  
 
For men who are  successfully  treated  surgically,  the serum  PSA level  should  decline  to below  
detectable  levels  within  21 to 30 days based  on its half-life.49,50 The reported  level of detectable  
serum  PSA by [CONTACT_211125] 0.1  ng/mL  (undetectable  levels  are expressed  as <0.1 
ng/mL).[ADDRESS_252462]  acceptable  threshold  for a detectable  PSA after prostatectomy  
is 0.05 ng/mL,  which  is a measurable  value  above  the level  detectable  by [CONTACT_135942].  In this trial all 
PSA assays  will be performed  at the location  of participant  registration  using  a routine  PSA 
assay.  
19 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252463],  in men with non-castrate  levels  of testosterone  and a rising  PSA 
following  radical  prostatectomy  without  clinically  metastatic  disease to determine  whether  
abiraterone  acetate  can potentially  cure (primary  endpoint:  progression -free surviv al at 18 months  
from  the time of treatment  initiation)  a proportion  of men of this population.  Men with pelvic  
and/or  retroperitoneal  nodes  < [ADDRESS_252464] definitive  metastases.  
 
2.2 Secondary  Objectives  
• To determine  the PSA response  rate. 
• To determine  the effects  of each arm on overall  quality  of life, with particular  attention  to 
libido,  potency,  anxiety,  depression,  hot flashes,  and fatigue.  
• To determine  the frequency  and intensity  of non-hematologic  adverse  events.  
• To determine  testosterone  and LH recovery  rates.  
 
3. PATIENT  SELECTION  
3.[ADDRESS_252465]-radical  prostatectomy men with a serum  testosterone  of 150 ng/dL  or greater who  now have 
a rising  PSA and a PSADT ≤ 9 months  without  metastatic  disease.  However,  patients  with pelvic  
and/or  retroperitoneal  nodes  < [ADDRESS_252466]  meet  all of the following  criteria:  
 
• Willing  and able to provide  written  informed  consent  and Authorization  for Use and Release  
of Health  and Research  Study  Information  (HIPAA  authorization)  
 
NOTE : HIPAA  authorization  may be either  included  in the informed  consent  or obtained  
separately.  
 
• Male  aged 18 years  and above  
 
• Patients  must  have undergone  local  treatment  via radical  prostatectomy  
 
o Patients  who have received  primary  radiation  therapy  followed  by a salvage  
radical  prostatectomy  are eligible.  
 
o Patients  who have had post-operative  radiation  therapy  for presumed  locally  
recurrent  disease  are eligible  
• Histologically  confirmed  prostate  cancer  (per standards at Institution  of participant  
registration)  currently  with progressive  disease,  defined  as: 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
20 of 69  
 o Rising  PSA (50%  or more  increase  to a level  of 1 ng/mL  or more,  based  on 
at least [ADDRESS_252467] 1 week  apart).  The 50% rise in PSA is 
across  the 3 determinations,  and these  determinations  do not need to be  sequential.  
 
AND  
 
o PSADT  ≤ 9 months  as calculated  according  to the Memorial  Sloan -Kettering  Cancer  
Center  nomogram  (http://www.mskcc.org/mskcc/html/[ZIP_CODE].cfm ) 
• Patients  with pelvic  and/or  retroperitoneal  nodes  < [ADDRESS_252468] definitive  metastases.  
 
• Patients  must have a serum  testosterone  of 150 ng/dL  or greater  
• ECOG performance  status  of ≤ 2 (Appendix  A) 
 
• Adequate  bone  marrow,  hepatic,  and renal  function,  as evidenced  within  14 days prior  to 
treatment  initiation  by: 
o Absolute neutrophil  count  (ANC)  ≥ 1500/mm3 
o Platelet  count ≥ 100,000/mm3 
o Hemoglobin  ≥ 9 g/dL without  need for hematopoietic  growth  factor  or transfusion  
support  within  30 days prior  to treatment  initiation  
o Aspartate  aminotransferase  (AST)  ≤ 1.5 times  the upper  limit of the normal  range  (x 
ULN)  
o Alanine  aminotransferase  (ALT)  ≤ 1.[ADDRESS_252469]  
o Total  bilirubin ≤ 1.[ADDRESS_252470]  
o Serum  creatinine  of ≤ 1.5 mg/dl  or Calculated  creatinine  clearance  of ≥ 60 mL/min  
o Serum  albumin  ≥ 3.0 g/dL 
o Serum  potassium  ≥ 3.5 mEq/L  
• At least 4 weeks  and recovery  to Grade  0‐1 from  reversible  effects  of prior  surgery  (i.e., 
incisional  pain,  wound  drainage)  
 
• Able  to swallow  the study  drug whole  as a tablet  
 
• Willing  to take abiraterone  acetate  on an empty  stomach;  no food should  be consumed  at least 
two hours  before  and for at least one hour after the dose of abiraterone  acetate  is taken  
 
• Patients  who have partners  of childbearing  potential  must  be willing  to use a method  of birth 
control  with adequate  barrier  protection  as determined  to be  acceptable  by [CONTACT_211126] [ADDRESS_252471] dose of abiraterone  acetate.  
 
3.3 Exclusion  Criteria  
Patients  that meet  any of the criteria  listed  below will  not be eligible  for study  entry:  
• Prior  cytotoxic  chemotherapy  or biologic  therapy  for prostate  cancer  
• More  than 8 months  of prior  hormonal  therapy  (e.g.,  gonadotropin -releasing  hormone  analogs,  
megestrol  acetate,  or Casodex)  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
21 of 69  
 Note : Patients  who have been on prior  hormonal  therapy must  wait at least 1 year 
after the drug is fully metabolized  to start treatment  on protocol.  
• Prior  ketoconazole,  abiraterone  acetate,  or enzalutamide  for the treatment  of prostate  cancer.  
• Known  brain  metastasis  or evidence  of metastatic  disease  by [CONTACT_3610],  physical  exam,  or bone  
scan within  4 weeks  of registration  
o Patients  with equivocal  uptake on a bone  scan that in the clinician’s  opi[INVESTIGATOR_211090]  
• Currently  active  second  malignancy,  except  non-melanoma  skin cancer  
• Significant  medical  condition  other  than cancer,  that would  prevent  consistent  and compliant  
participation  in the study  that would,  in the opi[INVESTIGATOR_1072],  make  this protocol  
unreasonably  hazardous  including  but not limited  to: 
o Active  infection  or other  medical  condition  that would  make  prednisone/prednisolone  
(corticosteroid)  use contraindicated  
o Severe  hepatic  impairment  (Child -Pugh  Class  C) 
o History  of gastrointestinal  disorders  (medical  disorders  or extensive  surgery)  that 
may interfe re with the absorption  of the study  agents  
o Uncontrolled  hypertension  (systolic  BP ≥ 160 mmHg  or diastolic  BP ≥ 95 mmHg);  
patients  with a history  of hypertension  are allowed  provided  blood  pressure  is 
controlled  by [CONTACT_14181]-hypertensive  treatment  
o Active  or symptomatic  viral hepatitis  or chronic  liver disease  
o History  of pi[INVESTIGATOR_211091]  
o Clinically  significant  heart  disease  as evidenced  by [CONTACT_211127],  or arterial  
thrombotic  events  in the past 6 months,  severe  or unstable  angina,  or [LOCATION_001]  
Heart  Association  (NYHA) Class  III or IV heart  disease  or cardiac  ejection  fraction  
measurement  of < 50 % at baseline  
o Atrial  fibrillation,  or other  cardiac  arrhythmia  requiring medical  therapy  
o Uncontrolled  diabetes  mellitus  
o Active  psychiatric  condition  
• Use of any prohibited  concomitant  medications  (Section  5.5.2)  within  30 days prior  to Cycle  
1, Day 1 
• Pre-existing  condition  that warrants  long-term corticosteroid  use in excess  of study  dose 
• Grade  > 2 treatment -related  toxicity  from  prior therapy  
• Known  allergies,  hypersensitivity  or intolerance  to abiraterone  acetate,  prednisone  or degarelix  
• Administration  of an investigational  therapeutic  within  30 days of Cycle  1, Day1  
• Any condition  which,  in the opi[INVESTIGATOR_1072],  would  preclude  participation  in this 
trial 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
22 of 69  
 4. PATIENT  REGISTRATION  
A centralized  registration  procedure  will be used.  After  eligibility  screening,  patients  who are 
selected  to participate  will be registered  with the Lead  Center  (MSKCC).  A record  of patients  
who fail to meet  entry  criteria  (i.e., screen  failures)  will be maintained.  Patient registration  must  
be complete  before  beginning  any treatment  or study  activities.  
 
4.1 Lead  Center  (MSKCC)  Registration  
Obtain  informed  consent,  by [CONTACT_11093].  
 
Confirm  eligibility  as defined  in the section  entitled  Criteria  for Patient/Subject  Eligibility.  
 
During  the registration  process  registering  individuals  will be required  to complete  a protocol  
specific  Eligibility  Checklist.  
 
All participants  must  be registered  through  the Protocol  Participant  Registration  (PPR)  Office  at 
Memorial Sloan -Kettering  Cancer Center.  PPR is available  Mond ay through  Friday  from  8:30am  
– 5:30pm  at [PHONE_214].  Registrations  must  be submitted  via PPR Electronic  Registration  
System  (http://ppr/ ). The completed  signature  [CONTACT_86506]/RA or verbal  script/RA,  
a completed  Eligibility  Checklist and other  relevant  documents  must  be uploaded  via the PPR  
Electronic  Registration  System.  
 
4.1.[ADDRESS_252472]  at Memorial  Sloan  Kettering  Cancer  
Center  (MSKCC)  via Prostate  Cancer  Clinical  Trials  Consortium,  LLC (PCCTC).  
 
To complete  registration  and enroll  a participant  from  another  institution,  the study  staff 
at that site  must  contact  [CONTACT_211128]/her  of the 
participant  registration.  The site staff then needs  to  email  registration/eligibility  
documents  to the PCCTC via email  at [EMAIL_4099] . 
 
The following  documents  must  be sent for each enrollment  within  24 hours  of the 
informed  consent  form  being  signed:  
 
• The completed  or partially  completed  MSKCC eligibility  checklist  
• The signed  informed  consent  and HIPAA  Authorization  form  
• Supporting  source  documentation  for eligibility  questions  (laboratory  results,  
pathology  report,  radiology  reports,  MD notes,  physical  exam  sheets,  medical  history,  
prior  treatment  records,  and EKG  report).  
 
Upon  receipt,  the research  staff at PCCTC will  conduct  an interim  review  of all 
documents.  If the eligibility  checklist is not complete  or source  documentation  is missing,  
the patient  will be registered  PENDING  and the site is responsible  for sending  completed  
registration  documents  within  [ADDRESS_252473]  is complete,  participant  meets  all criteria,  all source  documentation  is 
received,  the participating  site IRB has been activated  by [CONTACT_30588],  and the site is in good  
standing  with MSKCC,  the PCCTC  research  staff will send the completed  registration  
documents  to the MSKCC  Protocol  Participant  Registration  (PPR)  Office  to be enrolled  as 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
23 of 69  
 stated  in section  4.1. The participant  will be registered.  
 
Once  eligibility  has been established  and the participant  is registered,  the participant  will 
be assigned  an MSKCC Clinical  Research  Database  (CRDB)  number  (protocol  
participant  number).  This number  is unique  to the participant  and must  be written  on all 
data and correspondence  for the participant.  This protocol  participant  number  will be 
relayed  back  to study  staff at the registering  site via e-mail and will serve  as the 
enrollment  confirmation.  
 
4.1.3 Randomization  
Details  regarding  randomization  are found  in section  5.4. Staff at the registering  site will 
receive  the treatment  plan for the randomized  participants  via email  at the time they receive  
their participant  ID. 
 
4.2 Institutional  Registration  
Patient  registration  at each study  site/institution  will be conduc ted according  to the institution’s  
established  policies.  Patients  must  be registered  with MSKCC and their local  site/institution  
before  beginning  any treatment  or study  activities.  
 
4.2.1  Informed  consent  
Text regarding PCCTC should  be added  to all institutional  informed  consent  documents  
and sections  in the research  authorization/HIPAA forms  (e.g.,  “Prostate  Cancer  Clinical  
Trial  Consortium,  , [LOCATION_001],  NY”).  
 
Authorized  study  personnel  should  fully explain  the scope  of the study  (Section  6) to 
each patient  before  obtaining  informed  consent.  Patients  should  be advised  of any known  
risks inherent  in the planned  procedures,  any alternative  treatment  options,  their right to 
withdraw  from  the study  at any time for any reason,  and their right to privacy.  
 
When obtaining  informed  consent,  study  personnel  should:  
First : Confirm  that the patient  has received  the research  authorization/HIPAA form.  This 
must  be reviewed  before  confirming  eligibility  and obtaining  informed  consent.  
 
Next : Confirm  eligibility  as defined  in Sections  3.2 and 3.3 (Inclusion  and Exclusion  
Criteria).  
 
5. STUDY  TREATMENTS  
5.1 Description  of Treatments  
5.1.1 Study Drug  (Abiraterone  acetate)  
Abiraterone  acetate  250-mg tablets  are oval,  white  to off-white  and contain abiraterone  
acetate  and compendial  (USP/NF/EP)  grade  lactose  monohydrate,  microcrystalline  
cellulose,  croscarmellose  sodium,  povidone,  sodium  lauryl  sulfate,  magnesium  stearate,  
colloidal  silicon  dioxide,  and purified  water,  in descending  order  of concentration  (the 
water is removed  in tableting).  Abiraterone  acetate  must  be taken  on an empty  stomach.  
No food should  be consumed  for at least two hours  before  the dose of abiraterone  acetate  
is taken  and for at least one hour after the dose of abiraterone  acetate  is taken.  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
24 of 69  
 5.1.2 Degarelix  
Degarelix  is supplied  as a powder  to be  reconstituted  with Sterile  Water  for Injection,  
USP.  A starting  dose of 240 mg given  as two subcutaneous  injections  of 120 mg at a 
concentration  of 40 mg/mL  will be administered.  The starting  dose is followed  by 
[CONTACT_211129] 80 mg administered   per institutional  guidelines at a concentration  
of 20 mg/mL  every  28 days (± 3 days)  
 
5.1.3 Prednisone  
Prednisone  (5 mg tablets)  will be prescribed  to patients  assigned  abiraterone  acetate  to be 
taken  orally  once daily  with food. If a subject  has been receiving  glucocorticoids  other  
than prednisone  or prednisolone,  it will be necessary  to switch  the glucocorticoid  to 
prednisone  or prednisolone  5 mg once daily  prior  to Day 1. 
 
5.2 Treatments  Administered  
5.2.1 Group  1: Abiraterone  acetate  and prednisone  
Patients  randomized  to abiraterone  acetate  and prednisone  (Group  1) will be instructed  to 
take 1000 mg (four 250 mg tablets)  of abiraterone  acetate  orally  (PO)  at least 1 hour 
before  a meal  and 2  hours  after a meal  every  day. These  patients  will also be treated  with 
prednisone  5 mg once daily  with food.  
 
5.2.2 Group  2: Abiraterone  acetate  plus degarelix  and prednisone  
Patients  randomized  to abiraterone  acetate  plus degarelix  and prednisone  (Group  2) will 
be instructed  to take 1000  mg (four 250 mg tablets) of abiraterone  acetate  orally  (PO)  at 
least 1 hour before  a meal  and 2 hours  after a meal  every  day and prednisone  5 mg once  
daily  with food.  Patients  will also be given  two subcutaneous  injections  of degarelix  120 
mg on Cycle  1, Day  1(starting  dose) and 80 mg subcutaneous   doses  (maintenance  doses)  
every  28 days (±3 days)  thereafter.  
 
5.2.3 Group  3: Degarelix  alone  
Patients  randomize d to degarelix  alone  (Group  3) will be given  two subcutaneous  
injections  of degarelix  120 mg on Cycle  1, Day  1 (starting  dose)  and 80  mg subcutaneous  
doses  (maintenance  doses)  every  28 days (± 3 days)  thereafter.  
 
5.3 Selection  and Timing  of Dose  for Each  Patient  
Each treatment  cycle  consists  of 28 consecutive  days (4 weeks).  Patients  will take study  treatment  
for 8  cycles  (32 weeks)  or until disease  progression  or patient  withdrawal.  The treatments  are not 
blinded.  The dose of prednisone  will remain  unchanged  in the event  that the study  drug dose is 
changed.  The dose of prednisone  will only be changed  at the discretion  of the treating  physician.  
Treatment  with abiraterone  acetate  will be continuous  from  Day 1. If a dose is missed,  the next 
dose should  be given  as planned  without  making  up the missed  dose.  Degarelix  will be 
administered  approximately  every  [ADDRESS_252474] been  
met and the  patient  is registered  to the study.  Patients  will be randomized  to receive  abiraterone  
acetate  and prednisone  (Group  1), abiraterone  acetate  plus degarelix  and prednisone  (Group  2) or 
degarelix  alone  (Group  3) in a 1:1:1  ratio.  
25 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252475]  be documented.  The principal  investigator  
[CONTACT_210068] d be alerted  if the patient  is taking  any prohibited  agents.  Concurrent  enrollment  in another  
therapeutic  clinical  investigation  is prohibited.  
 
5.5.1 Supportive  care medications  
Supportive  care medications  are permitted  with their use following  institutional  
guidelines.  
 
The following  supportive  care medications  are considered  permissible  during  the study:  
• Conventional  multivitamins,  selenium  and soy  supplements  
• Additional  systemic  glucocorticoid  administration  such as “stress  dose”  
glucocorticoid  is permitted  if clinically  indicated  for a life threatening  medical  
condition,  and in such cases,  the use of steroids  will be documented  as concomitant  
drug 
 
5.5.2 Prohibited  within  30 days prior  to administration  of study  treatment  
• Spi[INVESTIGATOR_8407]  
• 5 α–reductase  inhibitors  (e.g.,  finasteride,  dutasteride)  
• Saw Palmetto  
• Use of other  investigational drug therapy  
 
5.5.3 Prohibited  before  enrollment  and during administration  of study  treatment  
• Androgen  Receptor  Partial  Agonists  
• Ketoconazole  (Ketoconazole  shampoo  or topi[INVESTIGATOR_211092]/ointment  for treatment  of a 
past fungal  infection  does not exclude  patients)  
• Previous  abiraterone  acetate  or other  investigational  CYP17  inhibitors  (e.g.,  TAK - 
700) 
• Chemotherapy  (e.g.,  docetaxel,  mitoxantrone,  vinorelbine)  
• Immunotherapy  (e.g.,  cancer  vaccines,  GM-CSF)  
• Estrogens  
• PC-SPES  or PC-HOPE  herb mixtures  Radiopharmaceuticals  (e.g.,  89Sr, 153Sm, 
Fludrocortisone  acetate)  
 
5.5.4 Prohibited  during  administration  of study  treatment  
• Antiandrogens  
o Non-steroidal  antiandrogens  (e.g.,  bicalutamide,  flutamide,  nilutamide)  
o Steroidal  antiandrogens  (e.g.,  megestrol  acetate,  cyproterone)  
 
5.5.5 The following  medications  are not excluded  or prohibited,  but are strongly  discouraged:  
26 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 • Digoxin;  hypokalemia  which  is an expected  adverse  effect  of abiraterone  
may enhance digoxin  toxicity.  Investigators  are encouraged  to consider  whether  
patients  needing  digoxin  could  be managed  with a different  drug.  
• Pomegranate  juice/supplements;  pomegranate  juice  has been associated  with 
stabilization  of PSA in a phase  II study.  
• Indole -3-carbinol;  indole -3-carbinol  has been suggested  to have estrogenic  effects,  
which  theoretically  could  affect  prostate  cancer.  However,  no clinical  trial results  in 
men with prostate  cancer  are available.  
 
• Flaxseed  Oil; flaxseed  oil has been associated  with having  estrogenic  and 
antiestrogenic  effects  and can potentially  lower  potassium  level.  Flaxseed  oil may 
theoretically  lead to progression  of some  forms  of cancer,  including  prostate  cancer.  
However,  no clinical  trial results  in men with prostate  cancer  are available.  
 
5.5.6 Potential  for drug-drug interactions  
Abiraterone  acetate  is an inhibitor  of the hepatic  drug-metabolizing  enzyme  CYP2D6  and 
CYP2C8.  In a CYP2D6  drug-drug interaction  trial, the Cmax  and AUC  of 
dextromethorphan  (CYP2D6  substrate)  were  increased  2.8- and 2.9-fold, respectively,  
when dextromethorphan  was given  with abiraterone  acetate  1,000  mg daily  and 
prednisone  5 mg twice  daily.  Avoid  co-administration  of abiraterone  acetate  with 
substrates  of CYP2D6  with a narrow therapeutic  index  (e.g.,  thioridazine).  If alternative  
treatments  cannot  be used,  exercise  caution  and consider  a dose reduction  of the 
concomitant  CYP2D6  substrate  drug.  
 
In a CYP2C8  drug-drug interaction  trial in healthy  subjects,  the AUC of pi[INVESTIGATOR_051]  
(CYP2C8  substrate)  was increased  by 46% when  pi[INVESTIGATOR_211093] a 
single  dose of 1,000  mg abiraterone  acetate.  Therefore,  patients  should be monitored  
closely  for signs  of toxicity  related  to a CYP2C8  substrate  with a narrow therapeutic  
index  if used concomitantly  with abiraterone  acetate.  
 
Based  on in vitro data,  abiraterone  acetate  is a substrate  of CYP3A4.  
 
In a dedicated  drug interaction  trial, co-administration  of rifampin,  a strong  CYP3A4  
inducer,  decreased  exposure  of abiraterone  by 55%. Avoid  concomitant  strong  CYP3A4  
inducers  during  abiraterone  acetate  treatment.  If a strong  CYP3A4  inducer must  be co- 
administered,  increase  the abiraterone  acetate  dosing  frequency.  
 
In a dedicated  drug interaction  trial, co-administration  of ketoconazole,  a strong  inhibitor  
of CYP3A4,  had no clinically meaningful  effect  on the pharmacokinetics  of abiraterone  
acetate  
 
 
5.6 Packaging  and Labeling  
Abiraterone  acetate  tablets  will be provided  to each site packaged  for patient  assignment  at the 
time of randomization.  Patients  will be provided  with a 30-day supply  to allow  for visits  to occur  
every  28 days with a  ± [ADDRESS_252476] or medically  qualified  staff 
will dispense  the study  treatment  to each patient  in accordance  with this protocol.  
27 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 Degarelix  will be prescribed  from  open pharmacy  stock.  
 
Prednisone  will be prescribed  by [CONTACT_56951].  
 
5.7 Storage  and Accountability  
5.7.1 Storage  requirements  
Store  at 20oC to 25oC (68oF to 77oF); excursions  permitted  to 15oC to 30oC (59oF to 
86°F) . 
This medicine  may cause harm  to the  unborn  child  if taken  by [CONTACT_211130].  
It should not be taken  by [CONTACT_211131] -feeding.  Women  who are pregnant  or 
who may be pregnant  should  wear  gloves  if they need  to touch  abiraterone  acetate  tablets.  
Study  staff and caregivers  should  be notified  of this information,  to ensure  the appropriate  
precautions  are taken.  
 
5.7.[ADDRESS_252477]  all study  drugs  administered  during  this trial on the drug- 
dispensing  log. 
The drug dispensing  log will contain  the following  information:  
• patient  initials  and study  identification  number  
• date(s)  of study  drug dispensed  
• quantity  of study  drug dispensed  
• drug lot number  
• expi[INVESTIGATOR_78288] (if known)  
• initials  of dispensing pharmacist  
Subjects  will be provided  with a diary  in which  to record  their intake  of study  drug.  
However,  the actual  number  of tablets  taken  by [CONTACT_211132].  
 
5.8 Criteria  for Discontinuation  of Study  Treatment  
In the absence  of treatment  delays  because  of adverse  events,  treatment  will continue  for 8 
months  until one of the following  criteria  applies:  
• Patient  decides  to withdraw  from  the study  
• PSA progression  determined  as follows:  
PSA is assessed  every  28 days (± 3 days)  using  a routine  PSA assay.  If a measured  PSA is 
higher  than the preceding  value,  then the rising  PSA will  be confirmed  in 4 weeks  (±  3 days).  
If that third PSA value  is higher  still and the range  of values  is 50% above  the baseline,  then 
the patient  is off study  treatment.  If not, the patient  will remain  on study,  and the PSA will  
once again  be checked  when  the patient  presents  for his monthly  clinic  visit.  
• Radiographic  progression  (in the opi[INVESTIGATOR_1072])  
• Intercurrent  illness  that prevents  further  administration  of treatment  
• Unacceptable  adverse  event(s)  that may or may not be directly  related  to treatment  but that, in 
the judgment  of the treating  physician,  makes  it dangerous  for the patient  to be retreated  
28 of 69 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 • General  or specific  changes  in the patient’s  condition  that render  the patient  
unacceptable  for further treatment,  in the judgment  of the investigator  
• Initiation  of non-study  therapy  for metastatic  prostate  cancer  
Because  an excessive  rate of withdrawals  can render  the study  uninterruptable,  unnecessary  
withdrawal  of patients  should  be avoided.  When  a patient  discontinues  treatment  early,  the 
investigator  should  make  every  effort  to contact  [CONTACT_211133]  a final evaluation.  The 
reason(s)  for withdrawal  should  be recorded.  
When protocol  therapy  is discontinued  based  on subject  or investigator  decision  and the subject  
has not withdrawn  consent,  that subject  will be followed  for adverse  events  (AEs)  for [ADDRESS_252478] dose of study  medication.  In the event  that a serious  adverse  event  (SAE)  regardless  
of causality  is ongoing  or newly  reported  [ADDRESS_252479]-Treatment  Follow -Up 
All patients  who complete  8 months  of protocol  therapy  will be followed  for 10 additional  
months  until one of the following  criteria  applies:  
• Patient  decides  to withdraw  from  the study  
• PSA progression  determined  as  detectable  PSA per the assay  at the institution  of registration  
and confirmed  by [CONTACT_211134].  
• Radiographic  progression  (in the opi[INVESTIGATOR_1072])  
• Initiation  of non-study  therapy  for metastatic  prostate  cancer  
 
 
6. STUDY  PROCEDURES  
The following  assessments  and procedures  will occur  during  the study.  A schedule  of assessments  
is provided  in Table  4. 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
29 of 69  
  
Table  4  Study Calendar  
 Screening  Treatment  Period  (8 cycles)   
Post-treatment  
Follow -up 
(Every  28 days ±7 
days for 10 months)  Within  30 days  
prior  to 
protocol  
therapy 
initiation  Within  14 days  
prior  to 
protocol  
therapy 
initiation   
Day 1 of each 28 
day cycle  (+ 3 
days)  Day 15 (+ 2 days) of 
cycles  1,2,3  
[Abiraterone  
treatment  arms  only]   
End of Treatment2 
Informed  consent and research  authorization  X      
Demographics,  medical  history  X      
Interim  medical  history  X  X  X X 
Physical  examination3 X  X  X X 
Histologic  and radiographic  confirmation  of 
disease  X      
ECOG  or Karnofsky performance  status  X  X  X X 
CT of the chest,  abdomen,  and pelvis  X    X8 X3,8 
Radionuclide  bone  scan X    X8 X3,8 
12-lead ECG  X      
ECHO or  MUGA  X      
Laboratory  tests4,7  X X X7 X X 
PSA  X X  X X 
Serum  testosterone  and LH X    X X 
PRO assessments  X  X  X X 
Correlative studies  (optional)8 X      
Toxicity/AE  assessment9 X -------------------------------- -------------------------------- -------------------------------- --------------------------------  X 
Concomitant  medications  X -------------------------------- -------------------------------- -------------------------------- --------------------------------  X 
Abiraterone acetate + Prednisone  (Arms  1 & 
2)6   Daily  x 8 months     
Degarelix injection  (Arms  2 & 3)6   Monthly  x 8 
months     
Abbreviations:  CT, computerized  tomography;  ECG,  electrocardiogram;  ECOG,  Eastern  Cooperative Group; LH, luteinizing  hormone;  MRI, magnetic resonance imaging;  
MUGA,  multiple  gated  acquisition;  PRO,  patient -reported  outcome  
1. Physical  examination  includes  vital signs.  Weight  will be recorded at  every  visit.  Height  will be recorded  at screening visit  only.  Vital  signs  include  upright  blood  pressure,  
heart  rate, respi[INVESTIGATOR_2842], and oral or aural  body  temperature.  
2. End of treatment  visit will take place 28 ± [ADDRESS_252480]-treatment  follow -up 10 (±14 days),  or if patient discontinues  follow -up for reasons  described  in Section  5.9 
4. Laboratory  tests are outlined  in Section  6.5.1  
5. Prostate tissue  samples will  be collected  for those  patients  who give their consent (Section 6.10)  
6. Daily  abiraterone  acetate administered  with once  daily  prednisone. Details  on all treatments  administered  are outlined  in Section 5.2  
7. Liver  function tests  (AST,  ALT  and total bilirubin) should be performed  on Day 15 (±2 days)  of the first three  cycles.  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252481] 
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
Informed  Consent  6.1 
31 of 69 12-187 A(15) Protocol.DOCX   
 Before  protocol -specified  procedures  are carried  out, consenting  professionals  will explain  full 
details  of the protocol  and study  procedures  as well as the risks involved  to participants  prior  to 
their inclusion  in the study.  Participants  will also be informed  that they are free to withdraw  from  
the study  at any time.  All participants  must  sign an IRB-approved  consent  form  indicating  their 
consent  to participate.  This consent  form  meets  the requirements  of the Code  of Federal  
Regulations  and the Institutional  Review  Board/Privacy  Board of  this Center.  The consent  form  
will include  the following:  
• The nature  and objectives,  potential  risks and benefits  of the intended  study.  
• The length  of study  and the likely  follow -up required.  
• Alternatives  to the proposed  study.  This will include  available  standard  and investigational  
therapi[INVESTIGATOR_014].  In addition,  patients  will be offered  an option  of supportive  care for therapeutic  
studies.  
• The name  [CONTACT_211166].  
• The right of the participant  to accept  or refuse  study  interventions/interactions  and to withdraw  
from  participation  at any time.  
• Text regarding  the PCCTC  should  be added  to all institutional  informed  consent documents  
and sections  in the research  authorization/HIPAA forms  (e.g.,  “Prostate  Cancer  Clinical  Trial  
Consortium”)  
 
Before  any protocol -specific  procedures  can be carried  out, the consenting  professional  will fully 
explain  the aspects  of patient  privacy  concerning  research  specific  information.  In addition  to 
signing  the IRB Informed  Consent,  all patients  must  agree  to the Research  Authorization  
component  of the informed  consent  form.  
 
Each participant  and consenting  professional  will sign the consent  form.  The participant  must  
receive  a copy  of the  signed  informed  consent  form.  
 
6.2 Medical  History  
Medical  history,  such as previous  treatments,  procedures,  and conditions  will be collected  during  
the screening  period.  
 
6.3 Physical  Examination  
Evaluations  should  be performed  by [CONTACT_211135].  
Weight  will be recorded  at every  visit.  Height  will be recorded  at screening  visit only.  
Vital  signs  include  upright  blood pressure,  heart  rate, respi[INVESTIGATOR_2842], and oral or aural  body  
temperature.  
 
6.4 Cardiac  Function  
To assess  cardiac  function at baseline,  a 12-lead ECG  and a  Multiple  Gated  Acquisition  (MUGA)  
scan should  be obtained.  Echocardiography  can be used if MUGA is not available  or when  
echocardiography  is standard  of care at the study  site. Baseline  measurement  of left ventricu lar 
ejection  fraction  (LVEF)  will be performed.  Control  hypertension  and correct  hypokalemia  before  
treatment.  Monitor  blood  pressure,  serum  potassium  and symptoms  of fluid retention  at least 
monthly  during  active  treatment.  
32 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
Clinical  laboratory  Tests  6.5  
  
6.5.1 Laboratory  parameters  
Clinical  laboratory  tests will include  the following  (Table 5): 
 
Table  5. List of laboratory  tests 
 
Hematology : 
 
- Hematocrit  (Hct)  
 
- Hemoglobin  (Hgb)  
 
- Platelet  count  
 
- Red blood  cell (RBC)  count  
 
- White  blood  cell (WBC)  count  with 
differential   
Serum  Chemistry : 
- Alkaline  phosphatase  (ALK -P) 
- Alanine  aminotransferase  (ALT;  SGPT)  
- Aspartate  aminotransferase  (AST;  SGOT)  
- Blood  urea nitrogen  (BUN)  
- Carbon  dioxide  (CO2)  
- Chloride  (Cl) 
- Creatinine  (Cr) 
- Glucose  (Glu)  
- Lactate  Dehydrogenase  (LDH)  
- Potassium  (K) 
- Sodium  (Na) 
- Total  bilirubin  
- Calcium  (Ca) 
- Albumin  (Alb)  
 
 
 
6.5.2 Sample  collection,  storage  and shippi[INVESTIGATOR_211094],  blood chemistry  collected  for the study.  
Samples  will be analyzed  at a facility  meeting  Clinical  Laboratory Improvement  
Amendments  (CLIA)  requirements  and/or  using  methods  documented  in a methods  
validation  report.  
 
6.6 Efficacy/Response  Assessments  
PSA will  be assessed  every  28 days (± 3 days)  using  a routine  PSA assay.  
 
6.6.1 Primary  efficacy  endpoint  
Progression -free survival  (PFS)  defined  as achieving  and maintaining  an undetectable  
PSA level  (per institution  of registration)  with a non-castrate  level  of testosterone  (>150  
ng/dL)  will be assessed  at 18 months  from  the start of randomization  (PSA0).  
 
6.6.2 Secondary  response  endpoint  
Treatment  response  defined  as achieving  and maintaining  an undetectable  PSA level  (per 
institution  of registration)  with a non-castrate  level of testosterone  (>150  ng/dL)  will be 
assessed  at 8 months  from  PSA0.  
 
6.7 Testosterone  and Luteinizing  Hormone  Recovery  Rates  
Serum  testosterone  and LH recovery  rates will be measured  at 8 months  from  the start of 
treatment  and at each month  of the 10 month  follow up period ( secondary  endpoint  measure ). 
 
6.8 Patient -reported  Outcomes  
Effects  of each arm on health -related  quality  of life will be assessed  via PRO Survey  (Appendix  
B) completed  on paper  by [CONTACT_211136]:  Screening,  each Day [ADDRESS_252482]-Treatment  Follow -up.  The following  adverse  
symptom  events will be assessed  by 15 items  from  the NCI PRO -CTCAE:  libido,  potency,  
anxiety,  depression,  hot flashes,  fatigue,  joint swelling,  muscle  discomfort,  diarrhea,  and cough.  
Quality  of life will also be assessed  by [CONTACT_211137]  (LASA) single  item 
33 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
measure of overall  quality  of life.51 This item has been  shown to  be more  responsive  than multi -  
 item measures  and to cause  less patient  burden,  and is used across  NCI cooperative  group  trials,  
particularly  in the NCCTG,  ACOSOG,  and CALGB.  All items  in the PRO Survey  employ  a 7- 
day recall  period.  The PRO Survey  contains  a total of 16 items  and will take 5-8 minutes  to 
complete.  
 
6.9 Safety  Evaluation  
Frequency  and intensity  of non-hematologic  adverse  events  will be recorded  (secondary  
endpoint  measure ) per Section  9.2. 
 
6.10 Correlative  Studies  
Baseline  tumor  tissue  will be collected  for those  patients  who give their consent  for correlative  
analyses  and pharmacogenomic  studies.  Tissue  blocks  (preferred)  or unstained  slides  known  to 
contain  cancer  should  be obtained  on primary  tumors  from  patients.  Tumor  tissue  from  the radical  
prostatectomy  is preferred;  however,  if it is unavailable,  tumor  from  a diagnostic  prostate  biopsy  
is acceptable.  All samples  will be processed  at MSK CC.  Sample  shipment  to the central  
laboratory  (MSKCC)  may occur  any time during  the study.  
 
Tissue  samples  will be utilized  for morphologic  assessment,  percent  tumor  involvement  (if 
applicable),  and immunohistochemistry.  The immunohistochemical  markers  assessed  may be AR, 
PTEN,  PSMA,  fatty acid synthase  (FASN),  phospho -AMPK,  phospho -ACC,  phospho -S6 kinase,  
phospho -Akt for the assessment  of the  AMPK,  lipid synthesis,  mTOR  pathways,  and 
immunological  markers.  
 
Gene  expression  profiling  may be performed  from  residual  samples  by [CONTACT_211138]  (e.g. qRT-PCR,  NanoString  DASL assay).  Tissue  or purified  DNA and  RNA from  
these  samples  may also be examined  to detect  genomic  abnormalities  (somatic  mutations,  
deletions,  amplifications)  in selected  genes  by [CONTACT_211139]  (e.g. FISH,  sequencing,  
microarrays).  
 
A Central  Laboratory  will analyze  all tissue  samples  collected  for the study.  Samples  will be 
analyzed  at a facility  meeting  regulatory  requirements  and/or  using  methods  documented  in a 
methods  validation  report.  
 
6.10.[ADDRESS_252483]  of the study  at or by  [CONTACT_211140].  
 
6.10.2  Storage,  handling  and disposal  
PCCTC and PI  [INVESTIGATOR_211095],  stored  and disposed  of at the end of the study  in accordance  with the terms  
of the applicable  consents  and permissions  for each donor  and in accordance  with all 
applicable  laws.  
 
7. STUDY  ACTIVITIES  
7.1 Within  30 Days Prior to Protocol  Therapy  Initiation  
Before  initiating  any screening  activities,  the scope  of the study  should  be explained  to each 
patient.  Patients  should  be advised  of any known  risks inherent  in the planned  procedures,  any 
alternative  treatment  options,  their right to withdraw  from  the study  at any time for any reason,  
and their right to privacy.  After  this explanation,  patients  should  be asked  to sign and date a 
34 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
research  authorization/HIPAA  form  and an IRB-approved  statement  of informed  consent  that  
 meets  the requirements  of the Code of Federal  Regulations  (Federal  Register Vol.  46, No. 17, 
January  27, 1981, part 50) 
The screening  visit will determine  patient  eligibility  according  to the inclusion  and exclusion  
criteria  (Sections  3.2 and 3.3). The following  assessments  will be performed  at this visit:  
• Obtain  informed  consent  and research  authorization  
• Record  demographics  (including  age) and medical  history  (including  prior  treatment  
for prostate  carcinoma  and PSA kinetics)  
• Interim  medical  history  
• Conduct  physical  exam  (vital  signs,  height/weight,  etc.) 
• Obtain  histologic  and radiographic  confirmation  of disease  
• Blood  samples  for serum  testosterone  and LH  levels  
• Assess  ECOG performance  status  (Appendix  A) 
• PRO Survey  (Appendix  B) 
• CT of the chest,  abdomen,  and pelvis  
• Radionuclide  bone  scan 
• ECG  
• MUGA or ECHO  
• Discuss  concurrent  medications  (see Section  5.5 for a listing  of medications  with the 
potential  for drug interactions)  
• Collection  of prostate  tissue  for correlative  studies  (optional;  see Section  6.10).  
Note : Tissue  blocks  (preferred)  or unstained  slides  known  to contain  cancer  should  be 
obtained  on primary  tumors  from  patients.  Tumor  tissue  from  the radical  
prostatectomy  is preferred;  however,  if it is unavailable,  tumor  from  a diagnostic  
prostate  biopsy  is acceptable.  Sample  shipment  to the central  laboratory may occur  
any time during  the study.  
Relevant  information  should  be documented.  The institut ional  registration  should  be finalized,  
and appropriate  documents  (i.e., signed  informed  consent,  research  authorization/HIPAA form,  
and supporting  source  documentation  for eligibility  questions)  faxed  or emailed  to the lead site. 
 
7.[ADDRESS_252484] include  the assessments  listed  below:  
• Blood  samples  for laboratory  tests (Section  6.5) and PSA 
 
7.3 Treatment  Period  (Day  1 ±3 days  to Week  32 ± 3 days)  
Patients  will receive  study  treatment  for up to eight  28-day treatment  cycles  or less if one of the 
following  occurs:  disease  progression,  unacceptable  toxicity,  death,  patient  refusal or treatment  
delay  beyond  the time frame  that is permitted  for each treatment  (See Section  5.8). All 
assessments  must  take place  before  scheduled  degarelix  injection  (Group  2 and Group  3). 
35 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
7.3.1  Day 1(± 3 days)   
 On Day 1 of every  28-day cycle  the following  study  activities  will occur  while  a patient  
is continuing  on protocol  therapy:  
• Interim  medical  history  
• Physical  exam  
• Assess  ECOG performance  status  (Appendix  A) 
• PRO Survey  (Appendix  B) 
• Toxicity/AE  assessment  
• Degarelix  injection  (Group  2 and Group  3) 
• Blood  samples  for laboratory  tests (Section  6.5) and PSA 
• Discuss  concurrent  medications  (see Section  5.5 for a listing  of medications  with the 
potential  for drug interactions)  
7.3.2 Day 15(± 2 days) – For patients  in the Abiraterone  acetate  treatment  arms  only 
On Day 15 of cycles  1, 2 and 3 the  following  study  activities  will occur  while  a patient  is 
continuing  on protocol  therapy:  
 
• Liver  function  laboratory  tests (AST,  ALT  and total bilirubin)  
 
7.3.3 End-of-treatment  
28 ± [ADDRESS_252485] dose for those  who 
discontinue  protocol  treatment  prematurely.  
• Interim  medical  history  
 
• Physical  exam  
• Assess  ECOG performance  status  (Appendix  A) 
• PRO Survey  (Appendix  B) 
• Toxicity/AE  assessment  
• Blood  samples  for laboratory  tests (Section  6.5) and PSA 
• Discuss  concurrent  medications  (see Section  5.5 for a listing  of medications  with the 
potential  for drug interactions)  
 
• Blood  samples  for serum  testosterone  and LH  levels  
 
• CT of the chest,  abdomen,  and pelvis  
 
Radionuclide  bone  scanPatients  withdrawn  from  the study  because  of AEs do not need  
blood  samples  for serum  testosterone  and LH  levels,  CT of the chest,  abdomen  and 
pelvis,  or a radionuclide  bone  scan at their End-of-treatment  visits.  
36 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252486]-treatment  Follow -up 
Patients  completing  8 cycles  of protocol  therapy,  in the absence  of documented  disease  
progression  or initiation  of non-study  therapy  for metastatic  prostate  cancer,  will be seen every 28 
days (± 7 days)  for up to [ADDRESS_252487]-treatment  follow -up visit:  
• Interim  medical  history  
• Physical  exam  
• Assess  ECOG performance  status  (Appendix  A) 
• PRO Survey  (Appendix  B) 
• Toxicity/AE  assessment  
• Blood  samples  for laboratory  tests (Section  6.5) and PSA 
• Discuss  concurrent  medications  
• Blood  samples  for serum  testosterone  and LH  levels  
• CT of the chest,  abdomen,  and pelvis  (Follow -up 10 only,  or for patients  who discontinue  
follow -up due to reasons  described  in section  5.9) 
• Radionuclide  bone  scan (Follow -up 10 only,  or for patients  who discontinue  follow -up due to  
reasons  described  in section  5.9) 
 
 
Patients  who have discontinued  protocol  treatment  due to AEs will be followed  until the adverse  
event  has either  resolved  or stabilized.  Reasons  for premature  withdrawal  should  be determined  
and noted.  
 
8. ADVERSE  EVENTS  
8.1 Definitions  
8.1.1 Adverse  Event  (AE) 
Any untoward  medical  occurrence  in a patient  or clinical  investigation  subject  
administered  a medicinal  product  and which  does not necessarily  have to have a causal  
relationship  with this treatment.  An AE can therefore  be any  unfavorable  and unintended  
sign (including  an abnormal  laboratory  finding),  symptom,  or disease  temporally  
associated  with the use of a medicinal  product,  whether  or not related  to the medicinal  
product.  
 
8.1.[ADDRESS_252488]  
Please  refer to Prescribing  Information  Packet  for all relevant  safety  information.  
 
8.1.3 Adverse  Drug Reaction  (ADR)  
A noxious  and unintended  response  to any dose of the drug (or biological)  product for 
which  there  is a reasonable  possibility  that the product  cause  the response.  ‘‘Reasonable  
possibility’’  means  there  is evidence  to suggest  a causal  relationship  between  the drug 
and the adverse  event.  Suspected  adverse  reaction  implies  a lesser  degree  of certainty  
about  causality  than adverse  reaction,  which  means  any adverse  event  caused  by a drug.  
37 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 8.1.4 J&J Medicinal  Product  
The specific  J&J drug under  study and any other  J&J medicinal  product.  
 
8.1.[ADDRESS_252489]  Quality  Complaint  (PQC)  
Any discrete  concern  that questions  the identity,  quality,  durability,  reliability,  safety,  
efficacy  or intended  performance  of a drug product.  
 
A complaint  may allege  an injury  or malfunction  associated  with the use of the drug 
product.  It may also involve  the design,  literature,  packaging,  advertising,  availability,  
physical  appearance  or promotion  of the drug product.  
 
8.1.6 Serious  Adverse  Event  (SAE)  
An adverse  event  or suspected  adverse  reaction  is considered  ‘‘serious’’  if it results  in 
any of the  following  outcomes:  
• Death,  
• A life-threatening  adverse  event,  
o An adverse  event  or suspected  adverse  reaction  is considered  ‘‘life -threatening’’  if 
its occurrence  places  the patient  or subject  at immediate  risk of death.  It does not 
include  an adverse  event or suspected  adverse  reaction  that, had it occurred  in a 
more  severe  form,  might  have  caused death.  
• Inpatient  hospi[INVESTIGATOR_40088],  
• A persistent  or significant  incapacity  or substantial disruption  of the ability  to conduct  
normal  life functions,  
• A congenital  anomaly/birth  defect,  
• Is a suspected  transmission  of infectious  agents  by a medicinal  product  
Important medical  events  that may not result  in death,  be life-threatening,  or require  
hospi[INVESTIGATOR_28613],  based  upon appropriate  medical  
judgment,  they may jeopardize  the patient  or subject  and may require medical  or surgical  
intervention  to prevent  one of the outcomes  listed  in this definition.  Examples  of such 
medical  events  include  allergic  bronchospasm  requiring  intensive  treatment  in an 
emergency  room  or at home,  blood  dyscrasias  or convulsions  that do not result  in 
inpatient  hospi[INVESTIGATOR_059],  or the development  of drug dependency  or drug abuse.  
 
8.1.7 Special  Reporting  Situations  
When  a report  contains  a J&J product,  an identifiable  patient,  and identifiable  reporter,  
the following  events  represent  Special  Reporting  Situations:  
 
• Overdose  of a Johnson  & Johnson  medicinal  product  
• Pregnancy  exposure  (maternal  and paternal)  
• Exposure  to a medicinal  product  from  breastfeeding  
• Suspected  abuse/misuse  of a medicinal  Johnson  & Johnson  product  
• Inadvertent  or accidental  exposure  to a medicinal  Johnson  & Johnson  product  
• Any failure  of expected  pharmacological  action  (i.e., lack of effect)  of a Johnson  & 
Johnson  medicinal  product  
38 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 • Unexpected  therapeutic  or clinical  benefit  from  use of  a Johnson  & Johnson  
medicinal  product  
• Medication  error  involving  a Johnson  & Johnson  product  (with  or without  patient  
exposure  to the medicinal  Johnson &  Johnson product,  e.g., name  [CONTACT_2976])  
• Suspected  transmission  of any infectious  agent via  a medicinal  product.  
 
8.[ADDRESS_252490]  has completed  participation  in the study  as follows:  
An SAE or Special  Reporting  Situation  must be reported  if it occurs  during  a subject’s  participation  in 
the Study  (whether  receiving  Study  Product  or not) and within  [ADDRESS_252491]  completes  
his/her  participation  in the Study  must be followed  until any of the following  occurs:  
• the event  resolves  or stabilizes;  
• the event  returns  to baseline  condition  or value  (if a baseline  value  is available);  
• the event  can be attributed  to agents(s)  other  than the Study  Product,  or to factors  unrelated  to 
Study  conduct.  
 
8.[ADDRESS_252492],  acceptable  medical  terms.  
 
The adverse  event  recorded  should  not be a procedure  or a clinical  measurement  (i.e., a laboratory  
value  or vital sign)  but should  reflect  the reason  for the procedure  or the diagnosis  based  on the 
abnormal  measurement.  Only  abnormal  laboratory  values  that are deemed  clinically  significant  by 
[CONTACT_211141]  
(per section  8.4). 
 
Preexisting  conditions  that worsen  in severity  or frequency  during  the Study  should  also be 
recorded  (a preexisting  condition  that does not worsen  is not an adverse  event).  
 
Further,  a procedure  or surgery  is not  an adverse  event;  rather,  the event  leading  to the procedure  
or surgery  is considered  an adverse  event.  Any event  requiring  in-patient  hospi[INVESTIGATOR_211096] a subject’s  participation  in a trial must  be reported  as an SAE.  
Hospi[INVESTIGATOR_211097]: 
 
A: Reasons  described  in the Protocol,  (e.g.,  drug administration,  protocol -required  testing)  
B. Surgery  or procedure  planned  prior  to entry  into the Study.  
 
If a clinical  significant  worsening  from  baseline  is observed  in any laboratory  or other test  
parameter  (e.g.,  electrocardiogram  (ECG),  angiogram),  physical  exam  finding,  or vital sign,  a 
corresponding  clinical  adverse  event  should  be recorded.  
 
If a specific  medical  diagnosis  has been made,  that diagnosis  or syndrome  should  be recorded  as 
the adverse  event,  whenever  possible.  However,  a complete  description  of the signs,  symptoms  
and investigations  which  led to the diagnosis  should  be provided.  For example,  if clinically  
significant  elevations  of liver function  tests are known  to be  secondary  to hepatitis,  “hepatitis”  
and not “elevated  liver function  tests”  should  be recorded.  If the cause  is not known,  the abnormal  
39 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252493] or finding  should  be recorded  as an adverse  event,  using  appropriate  medical  terminology  
(e.g.,  thrombocytopenia,  peripheral  edema,  QT prolongation).  
 
8.[ADDRESS_252494] information below.  The initial  report  should  include  the following  
information at  a minimum:  
• Protocol  # and title  
• Study identification number,  sex, age at time  of event  
• Date  the event occurred  
• Description of  the SAE  
• Causal  relations hip to  the study drug  
The PCCTC  SAE  Report  Form  (Appendix D) will be used  by [CONTACT_211142] 3 calendar days  of learning  of the 
event. When a life-threatening event or death  is unforeseen and indicates  
participants  or others  are at increased risk of harm,  participating sites  should  notify  
PCCTC  as soon as  possible  but within 24 hours  of the time  the participating  site 
becomes  aware  of the event.  Severity,  causality,  action taken,  concomitant  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
40 of 69 12-187 A(15) Protocol.DOCX   
 medications,  outcome,  etc should be  reported  to the PCCTC  as soon  as possible.  
Participating sites  are responsible  for reporting all  SAEs  to their local  IRB per local  
guidelines.  Local  IRB SAE  approvals/acknowledgmen ts must be  sent  to PCCTC  upon  
receipt.  
The PCCTC  will facilitate  all SAE  reporting to  the MSK  IRB/PB  and Janssen  Scientific  
Affairs,  LLC within 24 hours  of PCCTC  awareness  or identification of the event using  
the Janssen SAE  Report  Form  (Appendix C). PCCTC  is responsible  for informing  all 
participating sites  about  all unexpected  SAEs  that are either  possibly,  probably,  or 
definitely related  to the study intervention within 15 days  of receiving the  stamped  
SAE  report  from  the MSK  IRB/PB.  PCCTC  is responsible  for informing all  
participating sites  within  [ADDRESS_252495]  information  for the MSKCC  PI [INVESTIGATOR_211098]:  
Lead  Site Study  PI 
[INVESTIGATOR_211099],  MD 
Memorial  Sloan  Kettering  Cancer  Center  
Genitourinary Oncology Service  
[ADDRESS_252496]  
New  York, NY [ZIP_CODE]  
[EMAIL_4095]  
 
PCCTC : 
Prostate  Cancer  Clinical  Trials  Consortium  
Phone : [PHONE_4503]/646 -422-4383  
Email : [EMAIL_4099]  
 
8.5.[ADDRESS_252497],  Special  Reporting  Situations  and 
PQCs  will be transmitted  to Janssen  Scientific  Affairs,  LLC using  their Serious  Adverse  
Event  Form  (Appendix  C), which  must  be completed  and signed  by a member  of the 
investigational  team  within  24 hours  of becoming  aware  of the event.  PCCTC will  
facilitate  all submissions  to Janssen  Scientific  Affairs,  LLC.  
 
The following  methods  are acceptable  for transmission  of safety  information  to the 
COMPANY:  
 
• Electronically  vis Janssen  SECURE  email  service  at IIS-BIO-VIRO -  
[EMAIL_897] , or 
• For business  purposes  if SECURE  email  is non-functional;  
o Facsimile  (fax)  at [PHONE_2243],  of receipt  of which  is evidenced  in a 
successful  fax transmission  report  
 
8.5.3 Safety  Reports  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
41 of 69 12-187 A(15) Protocol.DOCX   
 PCCTC will  distribute  outside  safety  reports  from  Janssen  Scientific  Affairs,  LLC  to the 
participating  sites immediately  upon receipt.  Participating  sites are responsible  for 
submitting  safety  reports  to their local  IRB/PB  as per  their local  IRB guidelines.  All local  
IRB approvals/acknowledgments  of safety  reports  must  be sent to PCCTC upon  receipt.  
 
 
8.5.4 Unanticipat ed Problems  
Unanticipated  problems  involving  risks  to participants  or others  (UPs)  are defined  
as any incident,  experience  or outcome  that  meets  all of the following criteria:  
 
• Unanticipated  (in terms  of nature,  severity,  or frequency) given (a) the 
research  procedures  that  are described  in the protocol -related  documents,  
such  as the IRB-approved  research  protocol  and informed consent  
document; and (b) the  characteristics  of the subject population being  
studied; and  
 
• Related  or possibly related  to participating in the research  (possibly related  
means  there  is a reasonable  probability that the  incident,  experience  or 
outcome  may have been caused  by [CONTACT_211143]);  
and  
• Suggests  that the research  place  participants  or others  at a greater  risk of 
harm (including physical,  psychological,  economic,  or social  harm) than was  
previously known or recognized.  
 
Participating sites  are responsible  for reporting all  UPs to PCCTC  as soon as  possible  
but within 3 calendar  days  of learning of the event.  UPs that  are SAEs  should  be 
reported  to PCCTC  via SAE  Report  form  as per Appendix D. All other  UPs should be  
reported  to PCCTC  in a memo  signed  by [CONTACT_168761]. 
 
PCCTC  is responsible  for submitting UPs to the MSK  IRB/PB according to  
institutional guidelines.  In addition, PCCTC  is responsible  for notifying participating  
sites  of all non-SAE  UPs that  may  affect the sites.  
 
8.[ADDRESS_252498]  laboratory  tests 
before  and at regular  intervals  during  their participation  in this study  as specified  in Table  4. The 
NCI CTCAE  v4.0 will be used to grade  AEs.  
At each study  visit for the duration  of their participation  in the study,  patients  will be evaluated  
for AEs (all grades),  SAEs,  and AEs that require  study  drug interruption  or discontinuation.  
Patients  discontinued  from  the treatment  phase  of the study  for any reason will be evaluated  
approximately  [ADDRESS_252499]  common  adverse  reactions  (≥ 5%) related  to abiraterone  acetate  are joint swelling  or 
discomfort,  hypokalemia,  edema,  muscle  discomfort,  hot flush,  diarrhea,  urinary  tract infection,  
cough,  hypertension,  arrhythmia,  urinary  frequency,  nocturia,  dyspepsia,  factures  and upper  
respi[INVESTIGATOR_2826]  [see Adverse  reactions  (1.4.3) ] 
 
Following  prolonged  therapy  with corticosteroids,  subjects  may develop  Cushing’s  syndrome  
characterized  by [CONTACT_211144],  thin skin,  easy bruising,  and proximal  myopathy.  Withdrawal  
of the corticosteroid  may result  in symptoms  that include  fever, myalgia,  fatigue,  arthralgia,  and 
malaise.  This may occur even without  other  evidence  of adrenal  insufficiency.  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
42 of 69 12-187 A(15) Protocol.DOCX   
 8.6.1 Management  of hypokalemia  
Subjects  who experience  hypokalemia  are to be managed  as presented  in Table  7. 
 
Table  7. Hypokalemia  management  
Serum  K+ Grade  Action  Further  Action  or Maintenance  
 
Low K+ or history  
of hypokalemia    
Weekly  (or more  frequent)  
laboratory  electrolyte  evaluations.  Titrate  dose to maintain  a serum  
K+ ≥3.5 mM ≤5.0 mM (maintenance  
of subjects  at ≥4.0 mM is 
recommended)  
 
<3.5 mM – 3.0 mM  
1 Initiate  oral or i.v. K+ 
supplementation.  Consider  
monitoring  magnesium  and 
replacement  if needed.  Titrate  dose to maintain  a serum  
K+ >3.5 mM ≤5.0 mM (maintenance  
of subjects  at ≥4.0 mM is 
recommended)  
 
 
<3.0 mM – 2.5 mM  
 
3 Withhold  abiraterone  acetate  
(study)  treatment  and initiate  oral 
or i.v. K+ and cardiac  monitoring.  
Consider  monitoring  magnesium  
and replacement  if needed  Titrate  dose to maintain  a serum  
K+ >3.5 mM ≤5.0 mM (maintenance  
of subjects  at ≥4.0 mM is 
recommended)  
 
 
<2.5 mM  
 
4 Withhold  abiraterone  acetate  
(study)  treatment  and initiate  oral 
or i.v. K+ and cardiac  monitoring.  
Consider  monitoring  magnesium  
and replacement  if needed.   
 
Off study  
 
8.6.2 Management  of hypertension  
• If Grade  1 or 2  adverse  events  occur,  management  per investigator.  No study  
medication  dose reduction.  
• If Grade  [ADDRESS_252500] or add 
medications  to mitigate  the toxicity  or consider  the specific  mineralocorticoid  receptor  
blocker,  eplerenone.  When  hypertension  resolves  to ≤Grade  1, resume  study  
medication  at full dose.  
• If toxicity  recurs,  hold study medication,  and adjust  or add medications  to mitigate  the 
toxicity.  When  resolved  to ≤Grade  1, resume  study  medication  with the first dose level  
reduction  (3 tablets,  750 mg of study  medication).  
• If toxicity  recurs,  hold study medication,  and adjust  or add medications  to mitigate  the 
toxicity.  When  resolved  to ≤Grade  1, resume  study  medication  with the second  dose 
level  reduction  (2 tablets,  500 mg of study  medication).  
• If toxicity  recurs  despi[INVESTIGATOR_211100] 2 dose level  reductions,  
discontinue  study  medication.  
 
8.6.3 Management  of edema,  fluid retention  
• If pedal  edema  occurs,  supportive  management  per investigator.  No study  medication  
dose reduction.  
• If anasarca  or pulmonary  edema  requiring  supplemental  oxygen  occurs,  hold study  
medication.  Adjust or add medications  to mitigate  the toxicity  and consider  the 
specific  mineralocorticoid  receptor  blocker,  eplerenone.  When  toxicity  resolves  to 
≤Grade  1, resume study  medication  at full dose.  
• If toxicity  recurs,  hold study medication,  and adjust  or add medications  to mitigate  the 
toxicity.  When  resolved  to ≤Grade  1, resume  study  medication  with the first dose level  
reduction  (3 tablets,  750 mg of study  medication).  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
43 of 69 12-187 A(15) Protocol.DOCX   
 • If toxicity  recurs,  hold study medication,  and adjust  or add medications  to 
mitigate  the toxicity.  When  resolved  to ≤Grade  1, resume  study  medication  with the 
second  dose level  reduction  (2 tablets,  500 mg of study  medication).  
• If toxicity  recurs  despi[INVESTIGATOR_211100] 2 dose level  reductions,  
discontinue  study  medication  
 
8.6.4 Mana gement  of hepatic  impairment  
In patients  with baseline  moderate  hepatic  impairment (Child -Pugh  Class  B), reduce  the 
recommended  dose of abiraterone  acetate  to 250 mg once daily.  A once  daily  dose of 250  
mg in patients  with moderate  hepatic  impairment  is predicted  to result  in an area under  
the concentration  curve  (AUC)  similar  to the AUC  seen in patients  with normal  hepatic  
function  receiving  1,[ADDRESS_252501] month,  every  two weeks  for the following  
two months  of treatment  and monthly  thereafter.  If elevations  in ALT  and/or  AST greater  
than 5X upper  limit of normal  (ULN)  or total bilirubin  greater  than 3X ULN  occur  in 
patients  with baseline  moderate  hepatic  impairment,  discontinue  abiraterone  acetate  and 
do not  re-treat patients  with abiraterone  acetate.  
 
8.6.5 Management  of hepatotoxicity  
For patients  who develop  hepatotoxicity  during  treatment  with abiraterone  acetate  (ALT  
and/or  AST greater  than 5X ULN  or total bilirubin  greater  than 3X ULN),  interrupt  
treatment  with abiraterone  acetate  [see Warnings  and Precautions  (1.4.2)].  Treatment  
may be restarted  at a reduced  dose of 750 mg once daily  following  return  of liver  
function  tests to the patient’s  baseline  or to AST and ALT less than or equal  to 2.5X  ULN  
and total bilirubin  less than or equal  to 1.5X  ULN . For patients  who resume  treatment,  
monitor  serum  transaminases  and bilirubin  at a minimum  of every  two weeks  for three  
months  and monthly  thereafter.  
 
If hepatotoxicity  recurs  at the dose of 750 mg once daily,  re-treatment  may be restarted  at 
a reduced  dose of 500 mg once daily  following  return  of liver function  tests to the 
patient’s  baseline  or to AST and ALT  less than or equal  to 2.5X  ULN  and total bilirubin  
less than or equal  to 1.5X  ULN . 
 
If hepatotoxicity  recurs  at the reduced  dose of [ADDRESS_252502]  and/or  bilirubin  greater  than or 
equal  to 10X ULN  is unknown.  
 
8.6.6 Management  of other  non-mineralocorticoid  based  side effects  
• If Grade  1-2 toxicities  occur,  give supportive  care per institutional guidelines.  No 
study  medication  dose reduction.  
• If Grade  3 or higher  toxicities  occur,  including  headache  (interferes  with activities  of 
daily  living),  nausea  (total  parenteral  nutrition/intravenous  fluids),  vomiting  (6 or  
more  epi[INVESTIGATOR_211101] 24 hours,  total parenteral  nutrition/intravenous  fluids),  diarrhea  
(intravenous  fluids,  hospi[INVESTIGATOR_059],  hemodynamic  collapse),  or any other  toxicity  
judged  related  to study  treatment  is observed  where  the subjects  safety  is jeopardized,  
hold study  medication.  
• When  toxicity  resolves  to ≤ Grade  1, resume  study  medication  at full dose.  
44 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 • If toxicity  recurs,  hold study medication,  and adjust  or add medications  to 
mitig ate the toxicity.  When  resolved  to ≤ Grade  1, resume  study  medication  with the 
first dose level  reduction  (3 tablets,  750 mg of study  medication).  
• If toxicity  recurs,  hold study medication,  and adjust  or add medications  to mitigate  the 
toxicity.  When  resol ved to ≤ Grade  1, resume  study  medication  with the second  dose 
level  reduction  (2 tablets,  500 mg of study  medication).  
• If toxicity  recurs  despi[INVESTIGATOR_211102] 2 dose-level  reductions,  
discontinue  study  medication.  
 
8.6.7 Management  of concomitant  use with strong  CYP3A4  inducers  
Avoid  concomitant  strong  CYP3A4  inducers  (e.g.,  phenytoin,  carbamazepi[INVESTIGATOR_050],  rifampin,  
rifabutin,  rifapentine,  phenobarbital)  during  ZYTIGA  treatment.  Although  there  are no 
clinical  data with this dose adjustment  in patients  receiving  strong  CYP3A4  inducers,  
because  of the potential  for an interaction,  if a strong  CYP3A4  inducer  must  be co- 
administered,  increase  the ZYTIGA  dosing  frequency  to twice  a day  only during  the co- 
administration  period  (e.g.,  from  1,000 mg once daily  to 1,000 mg twice  a day).  Reduce  
the dose back to the previous  dose and frequency,  if the concomitant  strong  CYP3A4  
inducer  is discontinued.  
 
9. TREATMENT EVALUATION  AND  OUTCOMES  
All baseline  evaluations  will be performed  within  [ADDRESS_252503]-treatment  PSA changes  are not described  as “responses.”52   Moreover,  there  
are no clinically  validated  criteria  for PSA “response”  for subjects  with non-castrate  disease.  As 
such, outcome  reporting  based  on PSA percentage  declines,  or on the proportion  of subjects  
showing  normalization  of an abnormal  level  does not apply  to this subset  of subjects.  
 
9.1 Primary  Endpoint  
The primary  endpoint  is progression -free survival  (PFS)  defined  as an undetectable  PSA (using  a 
routine  PSA assay)  with non-castrate  level  of testosterone  (>150  ng/dL)  at [ADDRESS_252504]  will 
remain  on study.  
45 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 9.1.2 Soft tissue  complete  response  
In addition  to an undetectable  PSA,  any pathological  lymph  nodes (whether  target  or 
non‐target)  must  have reduction  in short  axis to <10 mm (Complete  Response  per 
RECIST)  in order  to meet  the criteria  for PFS.  
 
Outcome  in subjects  who develop  radiographically  evident  metastatic  disease  while  on 
study  will be considered  treatment  failures  independent  of their respective  PSA values.  
 
9.2 Secondary  Endpoints  
9.2.1 PSA response  rate 
The percentage  of patients  with a non-castrate  level of testosterone  (>150  ng/dL)  and an 
undetectable  PSA at 8 months  from  PSA0  will be measured.  
 
9.2.2 Testosterone  and luteinizing  hormone  recovery  rates  
Testosterone  and LH  recovery  rates will be measured  at 8 months  from the  start of 
randomization  and at each month  of the 10 month  follow up period.  
 
9.2.3 Quality  of life 
Effects  of each arm on quality  of life, specifically:  libido,  potency,  anxiety,  depression,  
hot flashes,  fatigue,  joint swelling,  muscle  discomfort,  diarrhea,  and cough,  and overall  
quality  of life, will be assessed  separately  for each item as the change  at 8 months  from  
Day 1 Cycle  1, and as area under  the curve  (AUC)  between  Day 1 Cycle  1 and  8 months  
after Day 1 Cycle  1. 
 
9.2.4 Safety  profile  
Safety  will be evaluated  according  to the NCI Common  Terminology  Criteria  for 
Adverse  Events  (CTCAE)  v4.0.  Safety  assessments  will be based  on medical  review  of 
adverse  event  reports  and the results  of vital sign measurements,  physical  examinations  
and clinical  laboratory  tests throughout  the conduct  of the study.  The incidence  of 
adverse  events  will be tabulated  and reviewed  for potential  significance  and clinical  
importance.  The frequency  and intensity  of non-hematologic  adverse  events  will be 
recorded  until the subject  has completed  his participation  in the study  (See Section  11.5).  
 
9.3 Tertiary  Endpoint  
9.3.1 Correlative  tissue  analysis  
Correlative  tissue  analysis  with clinical  outcomes  while  on study.  
 
10. DATA  REPORTING  AND  REGULATORY REQUIREMENTS  
10.1 Data  Collection  and Management  
Data collected  during  this study  will be entered  into a secure  database.  
 
10.1.1  Electronic  Case  Report Forms  (eCRFs)  
The participating  sites will enter  data remotely  into electronic  Case  Report  Forms  
(eCRFs)  using  the internet  based  MSK  and PCCTC Caisis  Electronic  Data Capture  
(EDC)  system.  Completion  Guidelines  will be created  by [CONTACT_211145].  . Access  and training  for 
PCCTC Caisis  EDC will  be made  available  to participating  sites upon  local  regulatory  
approval.  The participating  site PI [INVESTIGATOR_211103] a timely  manner.  
46 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252505]’s  research  record.  Source  documentation  must  include  a 
minimum  of two identifiers  to allow  for data verification.  MSK  will maintain  the 
confidentiality  of any subject -identifiable  information  it may encounter.  
 
10.1.[ADDRESS_252506]  maintain  all source  documents,  study  related  documents  and 
eCRFs  for 3 years.  
10.1.4  Source  Documentation  Submission  for Registration  at Participating  Sites 
Participating  sites should  email  any source  documentation  that corresponds  to data 
entered  at registration  to PCCTC at [EMAIL_4099] within  24 hours  (see Section  
4.1.2).  
10.1.5  Data  Submission  Timelines  
All baseline  data should  be transmitted  to PCCTC within  24 hours  of the visit.  
All study  data should  be transmitted  to PCCTC within  14 days of visit except  for SAE 
submission  (see Section  8.3.1)  as described  in the Data Management  Plan.  
10.1.6  Data  Review  and Queries  
PCCTC will  review  data and source  documentation  as it is submitted.   Data will be 
monitored  and source  data verified  as necessary  and discrepancies  will be sent as queries  
to the participating  sites.  In addition,  PCCTC will  review  data for logic,  consistency,  and 
obvious  anomalies.   Queries  will be sent by [CONTACT_211146].  
Participating  sites should  respond  to data queries  within  14 days of receipt.  
 
 
10.2 Study Monitoring  and Quality  Assurance  
Data  and Safety  Monitoring  
The Data and Safety  Monitoring  (DSM)  Plans  at Memorial  Sloan -Kettering  Cancer  Center  were  
approved  by [CONTACT_40137]  2001. The plans  address  the new policies  
set forth  by [CONTACT_211147]  “Policy  of the National  Cancer  Institute  for Data  
and Safety  Monitoring  of Clinical Trials”  which  can be found  at:  
http://www.cancer.gov/clinicaltri als/conducting/dsm -guidelines/page1 . The DSM Plans  at 
MSKCC  were  established  and are monitored  by [CONTACT_40138].   The MSKCC  
Data and Safety  Monitoring  Plans can  be found on the MSKCC  Intranet  at: 
http://inside2/clinresearch/Documents/MSKCC%20Data%20and%20Safety%20Monitoring%20P  
lans.pdf  
 
There  are several  different  mechanisms  by [CONTACT_211148],  safety,  and 
quality.  There  are institutional  processes  in place  for quality  assurance  (e.g.,  protocol  monitoring,  
compliance  and data verification  audits,  therapeutic  response,  and staff education  on clinical  
research  quality  assurance)  and departmental  procedures  for quality  control,  plus there  are two 
institutional  committees  that are responsible  for monitoring  the activities  of our clinical  trials  
47 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 programs.  There  are several committees:  Data  and Safety  Monitoring  Committee  (DSMC)  for 
Phase I  and II clinical  trials,  and the Data  and Safety  Monitoring  Board  (DSMB)  for Phase  III 
clinical  trials,  report  to the MSKCC  Research  Council  and Institutional  Review  Board.  As a 
moderate  risk trial, this study  will be monitored  by [CONTACT_211149].  
Since  therapeutic  efficacy  is a stated  primary  objective,  all sites participant’s  responses  are 
subject  to review  by [CONTACT_30588]’s  Therapeutic  Response  Review  Committee  (TRRC).   Radiology  
and additional  lab reports  will need to be obtained  from  the participating  sites for MSKCC  TRRC  
review  and confirmation  of response  assessment.  These  materials  must  be sent to MSKCC  
promptly  upon request  
 
 
10.2.[ADDRESS_252507]  accruals  and the completeness  of registration  
data. Routine  data quality  reports  will be generated  to assess  missing  data and 
inconsistencies.  Accrual  rates and the extent  and accuracy  of evaluations  and follow -up 
will be monitored  periodically  throughout  the study  period,  and potential  problems  will 
be brought  to the attention  of the Principal  Investigator  [INVESTIGATOR_211104].  
Each site participating  in the accrual  of participants  to this protocol  will be audited  at a 
minimum  of 10% of all subjects,  but at least 2 from  each site will be 100%  source  data 
verified  by [CONTACT_211150].   Auditing  will occur  once shortly  after initiation  of subject  
recruitment  at a site (once  at least [ADDRESS_252508] 1 
visit),  annually  during  the study  (or more  frequently  if indicated),  and at the end or 
closeout of the trial, for protocol  and regulatory  compliance,  data verification  and source  
documentation.  Audits  may be accomplished  in one of two ways:  (1) sending  source  
documents  and research  records  for selected  patients  from  participating  sites to the 
PCCTC for  audit,  or (2) on-site auditing  of selected  patient  records  at participating  sites.  
The audit  will include  a review  of source  documentation  to evaluate  compliance  for: 
 
• Regulatory/IRB  compliance  (review  of current  protocol  and amendments,  Informed  
consent  documents  and procedures,  annual  continuing  review  reports,  AEs/SAEs)  
• Protocol  defined  treatment  compliance  
• Subject  records  
1. Each  subject  is reviewed  to determine  that there  is a signed  and dated  consent  
form  
2. Adherence  to eligibility  criteria  
3. Baseline,  on study  and follow -up protocol  testing  
4. eCRF  completion  
 
Audit  findings  will be reviewed  by [CONTACT_976], [CONTACT_211167],  and disseminated  to the Site 
PIs and staff.  
 
In addition,  each participating  site accruing  participants  to this protocol  will be audited by  
[CONTACT_211151],  data verification  and source  
documentation.  Audits  of selected  participant  records  may be conducted  on-site or 
remotely.  
48 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 Audits  will be conducted  annually  at minimum,  and more  often  if significant  and/or  
repeated  findings  are identified  during  monitoring  visits.  The number  of participants  
audited  will be determined  by [CONTACT_211152].  
 
Each  audit  will be summarized  and a final report  will be sent to the PI [INVESTIGATOR_211105]  30 days of the audit.  The report  will include  a summary  of 
findings,  participant -specific  case review,  recommendations  on any performance  and/or  
shortcomings  and request  for corrective  action,  when  necessary.  When  corrective  action  
is required,  the participating  site must  reply  within  45 days of receipt  of the audit  report  
with their corrective  action  plan.  
 
 
11. STATISTICAL  METHODS  
11.1 General  Considerations  
A randomized  phase  2 screening  design  is used to compare  the efficacy  of abiraterone  acetate  and 
abiraterone  acetate  plus degarelix  to degarelix  alone  for prostate  cancer  patients  in the rising  PSA 
clinical  state.  It is anticipated  that the trial will remain  open to accrual  for 36 months  with an 
additional  18 month  follow -up after accrual closure.The  primary  endpoint  for the study  is 
achieving  and maintaining  a PSA  level  defined  by [CONTACT_211153](PSA0).  A patient  that achieves  and maintains  a PSA0  
will be denoted  as a success  in this design.  Patients  that are not followed  through  the [ADDRESS_252509] study  
treatment.  
 
11.2 Sample  Size Determination  
One hundred  and twenty  patients  will be randomized  to the three  treatment  groups.  Each  
abiraterone  acetate  group  will be compared  to the degarelix  alone  group.  With  40 patients  per 
group,  it is assumed  that the probability  of a success  in the degarelix alone  group  is ≤ 0.[ADDRESS_252510] 0.20 greater  than degarelix  alone  in the abiraterone -based  
groups.  Under  these  projections,  there  is greater  than an 80% chance  of finding  for either  
abiraterone -based  treatment  relative  to degarelix  alone  using  Fisher’s  exact  test with a one-sided  
0.[ADDRESS_252511] 1 dose of study  drug.  
49 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 11.4 Demographics  and Baseline  Characteristics  
Demographic  variables  will include  age, race,  ethnicity,  height,  and weight.  Baseline  disease  
characteristics  will include  time from  diagnosis,  time from  radical  prostatectomy  to PSA 
progression  and time from  radical  prostatectomy  to initiation  of study  drug.  
 
11.5 Safety  Analysis  
11.5.1  Adverse  events  
Safety  analysis  will be summarized  using  the Safety  Population  defined  as any patient  
receiving  any part of study  treatment.  
 
Extent  of exposure  to study  treatment  will be summarized  and details  will be provided.  
Treatment  emergent  adverse  events  (AEs)  are those  events  that occur or worsen  on or 
after first dose of study  drug up through  [ADDRESS_252512]  dose.  Adverse  events  will be 
coded using  the MedDRA coding  system  and all AEs will be graded  according  to the 
National  Cancer  Institute  Common  Terminology  Criteria  for Adverse  Events  (CTCAE)  
v4.0.  
 
11.5.[ADDRESS_252513] results  will be reported  according  to the NCI- 
CTCAE  Version  4.0 criteria.  
 
12. REGULATORY AND  PROTECTION  OF HUMAN SUBJECTS  
12.1 Roles and  Responsibilities  
12.1.1  Lead Site/Sponsor Principal  Investigator  
[INVESTIGATOR_211106]:  
• Responsibility for the  overall conduct of  the study at all participati ng sites  and 
for monitoring the  progress  of the study  
• Reviewing Adverse  Events  (AEs) and  Serious  Adverse  Events  (SAEs)  
• Reviewing data  from  all participating  sites  
 
12.1.2  PCCTC  
The PCCTC  is responsible  for performing the  following tasks:  
• Ensuring that IRB approval  has been  obtained  at each  participating  site prior  to 
the first patient registration at  that site,  and maintaining copi[INVESTIGATOR_211107].  
• Managing subject registration  
• Developi[INVESTIGATOR_211108]  
• CRF  development,  setup  of study database,  and subsequent design changes  
• Participating in review of  content of the CRF  against  the protocol  requiremen ts 
• EDC  system  administration  (user/site  accounts  setup,  maintenance  and 
revocation)  
• Data  review, cleaning,  query management and resolution  
• Establishing procedures  for documentation, reporting and submitting of AE’s  
and SAEs  to the PCCTC.  
• Reviewing AEs and SAEs  
• Submitting AEs and SAEs  to Janssen  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
50 of 69 12-187 A(15) Protocol.DOCX   
 • 
• Training participating sites  on EDC  
• Collecting and compi[INVESTIGATOR_211109] 
• Data  reviewing from  all participating  sites  
• Facilitating audits  by [CONTACT_211154],  or by [CONTACT_54966].  
• Overseeing the  management of study  drug  at pariticipating sites  
 
12.1.3  Participating Sites  
Participating sites  are responsible  for performing the  following tasks:  
• Following the  protocol  as written,  the guidelines  of Good Clinical  Practice  (GCP),  
and applicable Standard  Operating Procedures  (SOPs).  Registering all  patients  
with  the PCCTC  by [CONTACT_211155],  supporting source  
documentation, and  signed informed  consent  promptly.  
• Providing sufficient experienced  clinical  and administrative  staff  and adequate  
facilities  and equipment to  conduct a collaborative  trial  according to  the 
protocol  
• Maintaining regulatory binders  on site and providing  copi[INVESTIGATOR_211110]  
• Collecting and submitting  data  according to  the schedule  specified  by [CONTACT_211156]  
• Responding to  queries  in a timely  manner  
 
12.2 Ethical  Considerations  
This study  will be conducted  in compliance  with the protocol,  GCP  guidelines  established  by [CONTACT_211157],  and the ethical  standards  set forth  in the Declaration  
of Helsinki  2004  (available  at: www.laakariliitto.fi/e/ethics/helsinki.html).  
 
12.[ADDRESS_252514]/Privacy  Board  (IRB/PB).  There  will be one protocol  document  and each 
participating  site will utilize  that document.  
 
The following  documents  must be provided  to PCCTC  before  the participating  site can be initiated  and 
begin  enrolling  participants:  
• Participating  Site IRB approval(s)  for the protocol,  appendices,  informed  consent  form and 
HIPAA  authorization  
• Participating  Site IRB approved  informed  consent  form and HIPAA  authorization  
• Participating  Site IRB’s  Federal  Wide  Assurance  number  and OHRP  Registration  number 
• Curriculum  vitae and medical  licenses  for each investigator  and consenting  professional  
• Documentation  of Human  Subject  Research  Certification  training  for investigators  and key 
staff members  at the participating  site 
• Documentation  of Good  Clinical  Practice  (GCP)  training  for the PI [INVESTIGATOR_6254]-PI [INVESTIGATOR_211111] 
• Participating  site laboratory  certifications  and normals  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
51 of 69 12-187 A(15) Protocol.DOCX   
 Upon  receipt  of the required  documents,  PCCTC will  submit  a participating  site activation  
request to MSKCC.  Once  approved,  MSKCC  will formally  contact  [CONTACT_211158].  
 
12.[ADDRESS_252515]  be organized  and documented  by [CONTACT_211150],  
reviewed  and approved  by [CONTACT_211159],  LLC,  and approved  by [CONTACT_211160]/PB.  Protocol  amendments  that affect  MSK  only (e.g. change  in MSK  Co-Investigator,  MSK  
translation,  etc.) do not require  IRB review  at the  participating  sites.  All other  protocol  
amendments  will be immediately  distributed  to each participating  site upon  receipt  of MSK  
IRB/PB  approval.  
Each participating  sites must  obtain  approval  for all amendments  from  their IRB within  90 
calendar  days of MSK  IRB/PB  approval.  If the amendment  is the result  of a safety  issue or makes  
eligibility  criteria  more  restrictive,  participating  sites will not be permitted  to continue  enrolling  
new participants  until site IRB approval  of the revised  protocol document  granted and submitted  
to the PCCTC,  who will in turn submit  the approval  docume naton  to MSKCC.  
 
The following  documents  must be provided  to PCCTC  for each amendment  within  the stated  timelines:  
• Participating  Site IRB approval  
• Participating  Site IRB approved  informed  consent  form  and HIPAA authorization  
 
PCCTC is  responsible  for submitting  all participating  site local  IRB approvals  and/or  
acknowledgments  to MSK  upon receipt  
12.5 Additional  IRB Correspondences  
Continuing  Review  Approval  
The Continuing  Review  Approval  letter  from  the participating  site’s  IRB and the  most  current  
approved  version  of the informed  consent  form  should  be submitted  to PCCTC within  7 days of 
expi[INVESTIGATOR_1516].  Failure  to submit  the re-approval  in the stated  timeline  will result  in suspension  of new 
participant  enrollment.  PCCTC is  responsi ble for submitting  all participating  site local  IRB 
approvals  and/or  acknowledgments  to MSK  upon  receipt.  
 
Deviations  
A protocol  deviation  on this study  is defined  as any incident  involving  non-adherence  to an  IRB 
approved  protocol.  Deviations  typi[INVESTIGATOR_211112] a significant  effect  on the rights,  safety,  or 
welfare  of research  participants  or on  the integrity  of the resultant  data.  Deviations  that represent  
unanticipated  problems  involving  risks to participants  or others,  or serious  adverse  events  should  
be reported  according  to sections  8.5.[ADDRESS_252516]  the rights  and/or  welfare  of the participant  or the scientific  
validity  of the study  and are related  to protocol  scheduling  changes  outside  of the allowed   
window due to a holiday  (e.g.,  New  Year’s,  Thanksgiving,  etc.) and/or  inclement  weather  or other  
natural event  do not require  reporting  to the PCCTC.  However,  they must  be clearly  documented  
in the patient’s  medical  record . 
 
Prospective  Deviations  
 
Deviations  to the research  protocol  that involve  patient  eligibility,  an informed  consent  procedure  
change,  and/or  treatment/pharmacy  alterations  that are not allowed  by [CONTACT_211161]/PB  prior  to the change  being  carried  out. Participating  
sites should  contact  [CONTACT_211162]/PB.  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
52 of 69 12-187 A(15) Protocol.DOCX   
 Retrospective  Deviations  
 
Deviations  that include  a change  or departure  from  the research  protocol  without  prior  approval  
from  the MSK  IRB/PB  are considered  retrospective  deviations.  Retrospective  deviations  should  
be reported  to PCCTC  as soon as possible,  who will in turn report  the deviation  to the MSK  
IRB/PB  as per  MSK  guidelines.  
 
Participating  Site IRB Reporting  
 
Participating  sites should  report  all deviations  to their institution’s  IRB per local  guidelines.  
Approvals/acknowledgments  from  the participating  site IRB for protocol  deviations  should  be 
submitted  to PCCTC who  will in turn submit  to MSK  IRB/PB  upon receipt.  
 
Other  correspondence  
Participating  sites should  submit  other  correspondence  to their institution’s  IRB according  to local 
guidelines,  and submit  copi[INVESTIGATOR_211113].  PCCTC  is responsible  for submitting  
all participating  site local IRB correspondences  to MSK  upon  receipt.  
 
12.6 Written  Informed  Consent  
Patients  will be required  to sign and date (in triplicate)  a statement  of informed  consent  that meets  
the requirements  of the Code  of Federal  Regulations  (Federal  Register  Vol. 46, No. 17, January  
27, 1981, part 50) and the IRB.  The medical  record  will include  a statement  that written  informed  
consent  was obtained  (and document  the date that it was obtained)  before  the patient  is enrolled  in 
the study.  The original  signed  document  will become  part of the patient’s  medical  record,  a copy  
will be forwarded  to the lead site pursuant  to registration  and to the PCCTC,  and a copy  will be 
sent home  with each patient.  Details  regarding  Informed  Consent  can be found  in Section  6.1. 
Informed  Consent  Procedures  for Participating  Sites  
 
The investigators  listed  on the Consenting  Professionals  Lists  at each participating  site may 
obtain  informed  consent  and care for the participants  according  to Good  Clinical  Practice  and 
protocol guidelines  
 
12.7 Protection  of Privacy  
Patients  will be informed  of the extent  to which  their confidential  health  information  generated  
from  this study  may be used for research  purposes.  After  this discussion,  they will be asked  to 
sign a research  authorization/HIPAA form.  The original  signed  documents  will become  part of 
the patient’s  medical  records,  and each patient  will receive  a copy  of the signed  documents.  The 
use and disclosure  of protected  health  information  will be limited  to the individuals  described  in 
the research  authorization  form.  The research  authorization  form  must  be completed  by [CONTACT_211163]  [INVESTIGATOR_211114]. 
 
12.8 Terminating  or Modifying  the Study  
Adverse  event  and laboratory  data from  this trial will be assessed  by [CONTACT_211164].  SAEs  will be reviewed  as they are reported  to the lead site/sponsor  and PCCTC  and the 
principal  investigator  [INVESTIGATOR_211115].  This assessment  will be shared  with the investigators  either  in writing  or as part of a 
teleconference.  Should  the assessment  of either  the lead site or the principal  investigator  [INVESTIGATOR_211116],  the study  will be closed  to further accrual.  Patients  who are 
receiving  an investigational  agent  will be assessed  individually  by [CONTACT_211165]’ best  interest to continue,  which  might  be the case for a patient  that is responding  to 
the intervention.  Follow -up safety  assessments  will be performed  for all patients  who are 
terminated  from  the study  prematurely.  
53 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 12.9 Noncompliance  
If a participating  site is noncompliant with the protocol document,  accrual  privileges  may be suspended  
and/or  contract  payments  may be withheld,  until the outstanding  issues  have been resolved.  
 
 
13. REFERENCES  
1. Holzbeierlein  J, Lal P, LaTulippe  E, et al: Gene  expression  analysis  of human  prostate  
carcinoma  during  hormonal therapy  identifies  androgen -responsive  genes  and mechanisms  of therapy  
resistance.  Am J Pathol  164:217 -27, 2004  
2. McLeod  D, Zinner  N, Tomera  K, et al: A phase  3, multicenter,  open -label,  randomized  
study  of abarelix  versus  leuprolide  acetate  in men with prostate  cancer.  Urology  58:756 -61, 2001  
3. Tomera  K, Gleason  D, Gittelman  M, et al: The gonadotropin -releasing  hormone  
antagonist abarelix  depot versus  luteinizing  hormone  releasing  hormone  agonists  leuprolide  or goserelin:  
initial  results  of endocrinological  and biochemical  efficacies  in patients  with prostate  cancer.  J Urol 
165:1585 -9, 2001  
4. Trachtenberg  J, Gittleman  M, Steidle  C, et al: A phase  3, multi center,  open  label,  
randomized  study  of abarelix  versus  leuprolide  plus daily  antiandrogen  in men with prostate  cancer.  J 
Urol 167:1670 -4, 2002  
5. Kim D, Gregory  CW, French  FS, et al: Androgen  receptor  expression  and cellular  
proliferation  during  transition  from  androgen -dependent  to recurrent  growth  after castration  in the 
CWR22  prostate  cancer  xenograft.  Am J Pathol  160:219 -26, 2002  
6. Stephenson  AJ, Kattan  MW,  Eastham  JA, et al: Prostate  cancer -specific  mortality  after 
radical  prostatectomy  for patients  treated  in the prostate -specific  antigen  era. J Clin Oncol  27:4300 -5, 
2009  
7. D'Amico  AV, Moul  J, Carroll  PR, et al: Cancer -specific  mortality  after surgery  or 
radiation  for patients  with clinically  localized  prostate  cancer  managed  during  the prostate -specific  
antigen  era. J Clin Oncol  21:2163 -72, 2003  
8. Crook  J, Ludgate  C, Malone  S, et al: Final report  of multicenter  Canadian  Phase  III 
randomized  trial of 3 versus  8 months  of neoadjuvant  androgen  deprivation  therapy  before  conventional - 
dose radiotherapy  for clinically  localized  prostate  cancer.  Int J Radiat  Oncol  Biol Phys  73:327 -33, 2009  
9. Freedland  SJ, Moul  JW: Prostate  specific  antigen  recurrence  after definitive  therapy.  J 
Urol 177:1985 -91, 2007  
10. Yossepowitch  O, Bianco  FJ, Jr., Eggener  SE, et al: The natural  history  of noncastrate  
metastatic  prostate  cancer  after radical  prostatectomy.  Eur Urol 51:940 -7; discussion  947-8, 2007  
11. Antonarakis  ES, Feng  Z, Trock  BJ, et al: The natural history  of metastatic  progression  in 
men with prostate -specific  antigen  recurrence  after radical  prostatectomy:  long-term follow -up. BJU Int, 
2011  
12. Pi[INVESTIGATOR_94899] -Gebhart  MJ, Procter  M, Leyland -Jones  B, et al: Trastuzumab  after adjuvant  
chemotherapy  in HER2 -positive  breast cancer.  N Engl J Med  353:1659 -72, 2005  
13. Martin  M, Pi[INVESTIGATOR_118487]  T, Mackey  J, et al: Adjuvant  docetaxel  for node -positive  breast  
cancer.  N Engl J Med 352:2302 -13, 2005  
14. Andre  T, Boni  C, Mounedji -Boudiaf  L, et al: Oxaliplatin,  fluorouracil,  and leucovorin  as 
adjuvant  treatment  for colon  cancer.  N Engl J Med  350:2343 -51, 2004  
15. Dematteo  RP, Ballman  KV, Antonescu  CR, et al: Adjuvant  imatinib  mesylate  after 
resection  of localised,  primary  gastrointestinal  stromal  tumour:  a randomised,  double -blind,  placebo - 
controlled  trial. Lancet  373:1097 -104, 2009  
16. Winton  T, Livingston  R, Johnson  D, et al: Vinorelbine  plus cisplatin  vs. observation  in 
resected  non-small -cell lung cancer. N  Engl J Med  352:2589 -97, 2005  
54 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 17. Sasagawa  I, Kubota Y, Nakada  T, et al: Influence  of luteinizing  hormone -releasing  
hormone  analogues  on serum  levels  of prostatic  acid phosphatase  and prostatic  specific  antigen  in patients  
with metastatic  carcinoma  of the prostate.  Int Urol Nephrol  30:745 -53, 1998  
18. Klotz  L, Boccon -Gibod  L, Shore  ND, et al: The efficacy  and safety  of degarelix:  a 12- 
month,  comparative,  randomized,  open -label,  parallel -group  phase  III study  in patients  with prostate  
cancer.  BJU Int 102:15 31-8, 2008  
19. Scher  HI, Heller  G: Clinical  states  in prostate  cancer:  toward  a dynamic  model  of disease  
progression.  Urology  55:323 -7, 2000  
20. Armstrong  AJ, Garrett -Mayer  E, de Wit R, et al: Prediction  of survival  following  first- 
line chemotherapy  in men with castration -resistant  metastatic  prostate  cancer.  Clin Cancer  Res 16:203 -11, 
2010  
21. Halabi  S, Small  EJ, Kantoff  PW, et al: Prognostic  model  for predicting  survival  in men 
with hormone -refractory  metastatic  prostate  cancer.  J Clin Oncol  21:1232 -7, 2003  
22. Smaletz  O, Scher  HI, Small  EJ, et al: Nomogram  for overall  survival  of patients with 
progressive  metastatic  prostate  cancer  after castration.  J Clin Oncol  20:3972 -82, 2002  
23. Shulman  MJ, Benaim  EA: Prognostic  model  of event -free survival  for patients  with 
androgen -independent  prostate  carcinoma.  Cancer  103:2280 -6, 2005  
24. Eastham  JA, Scardino  PT, Kattan  MW:  Predicting  an optimal  outcome  after radical  
prostatectomy:  the trifecta  nomogram.  J Urol 179:2207 -10; discussion  2210 -1, 2008  
25. Slovin  SF, Wilton  AS, Heller  G, et al: Time  to detectable  metastatic  disease  in patients  
with rising  prostate -specific  antigen  values  following  surgery  or radiation  therapy.  Clin Cancer  Res 
11:8669 -73, 2005  
26. Freedland  SJ, Humphreys  EB, Mangold  LA, et al: Death  in patients  with recurrent  
prostate  cancer  after radical  prostatectomy:  prostate -specific  antigen  doubling  time subgroups  and their 
associated  contributions  to all-cause  mortality.  J Clin Oncol  25:1765 -71, 2007  
27. D'Amico  AV, Moul  JW, Carroll  PR, et al: Surrogat e end point  for prostate  cancer - 
specific  mortality  after radical  prostatectomy  or radiation  therapy.  J Natl Cancer  Inst 95:1376 -83, 2003  
28. Ryan  CJ, Smith  A, Lal P, et al: Persistent  prostate -specific  antigen  expression  after 
neoadjuvant  androgen  depletion:  an early  predictor  of relapse  or incomplete  androgen  suppression.  
Urology  68:834 -9, 2006  
29. Titus  MA, Schell  MJ, Lih FB, et al: Testosterone  and dihydrotestosterone  tissue  levels  in 
recurrent  prostate  cancer.  Clin Cancer  Res 11:4653 -7, 2005  
30. Geller J, Albert  J, Nachtsheim  D, et al: Steroid  levels  in cancer  of the prostate --markers  
of tumor  differentiation  and adequacy  of anti-androgen  therapy.  Prog  Clin Biol Res 33:103 -11, 1979  
31. Suzuki  K, Nishiyama  T, Hara  N, et al: Importance  of the intracrine  metabolism  of adrenal  
androgens  in androgen -dependent  prostate  cancer.  Prostate  Cancer  Prostatic  Dis 10:301 -6, 2007  
32. Nelson  PS, Han D, Rochon  Y, et al: Comprehensive  analyses  of prostate  gene expression:  
convergence  of expressed  sequence  tag databases,  transcript  profiling  and proteomics.  Electrophoresis  
21:1823 -31, 2000  
33. Montgomery  RB, Mostaghel  EA, Vessella  R, et al: Maintenance  of intratumoral  
androgens  in metastatic  prostate  cancer:  a mechanism  for castration -resistant  tumor  growth.  Cancer  Res 
68:4447 -54, 2008  
34. Stanbrough  M, Bubley  GJ, Ross  K, et al: Increased  expression  of genes  converting  
adrenal  androgens  to testosterone  in androgen -independent  prostate  cancer.  Cancer  Res 66:[ADDRESS_252517], Lin DW,  et al: Intraprostatic  androgens  and androgen -regulated  
gene expression  persist  after testosterone  suppression:  therapeutic  implications  for castration -resistant  
prostate  cancer.  Cancer  Res 67:5033 -41, 2007  
36. U.S. Food  and Drug  Administration  Center  for Drug  Evaluat ion and Research:  Viadur  
(Leuprolide  Acetate  Implant)  Drug  Approval  Package,  Application  No.:  21-088,  
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/02 -1088_Vidaur.cfm , March  3, 2000  
55 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252518]  (Leuprolide  Acetate)  Injectable  Suspension  Drug  Approv al Package,  
Application  No.:  21-343, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/[ADDRESS_252519].cfm , 
U.S. Food  and Drug  Administration  Center  for Drug  Evaluation  and Research,  January  23, 2002  
38. Degarelix  Injection  Drug  Approval  Package,  Application  No.:  022201,   
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_TOC.cfm , U.S. Food  and Drug  
Administration  Center  for Drug  Evaluation  and Research,  December  24, 2008 
39. Klotz  LH, O'Callaghan  CJ, Ding  K, et al: A phase  III randomized  trial comparing  
intermittent  versus  continuous  androgen  suppression  for patients  with PSA progression  after radical  
therapy:  NCIC  CTG  PR.7/SWOG JPR.7/CTSU  JPR.7/[LOCATION_006]  Intercontinental  Trial  CR[LOCATION_006]E/01/013  J Clin 
Oncol  29:abstr  3, 2011  
40. Hussain  M, Goldman  B, Tangen  C, et al: Prostate -specific  antigen  progression  predicts  
overall  survival  in patients  with metastatic  prostate  cancer:  data from  Southwest  Oncology  Group  Trials  
9346 (Intergroup  Study  0162)  and 9916.  J Clin Oncol  27:2450 -6, 2009  
41. Bruchovsky  N, Klotz  L, Crook  J, et al: Locally  advanced  prostate  cancer --biochemical  
results  from  a prospective  phase  II study  of intermittent  androgen  suppression  for men with evidence  of 
prostate -specific  antigen  recurrence  after radiotherapy.  Cancer  109:[ADDRESS_252520]  G, Reid AH, Yap TA, et al: Phase  I clinical  trial of a selective  inhibitor  of CYP17,  
abiraterone  acetate,  confirms  that castration -resistant  prostate  cancer  commonly  remains  hormone  driven.  
J Clin Oncol  26:[ADDRESS_252521]  G, Reid AH, A'Hern  R, et al: Selective  inhibition  of CYP17  with abiraterone  
acetate  is highly  active  in the treatment  of castration -resistant  prostat e cancer.  J Clin Oncol  27:[ADDRESS_252522]  G, Danila  DC, et al: Significant  and sustained  antitumor  activity  in post - 
docetaxel,  castration -resistant  prostate  cancer  with the CYP17  inhibitor  abiraterone  acetate.  J Clin Oncol  
28:1489 -95, 2010  
45. de Bono  JS, Logothetis  CJ, Molina  A, et al: Abiraterone  and increased  survival  in 
metastatic  prostate  cancer.  N Engl J Med 364:1995 -2005,  2011  
46. O'Donnell  A, Judson I, Dowsett  M, et al: Hormonal  impact  of the 17alpha - 
hydroxylase/C(17,20) -lyase  inhibitor  abiraterone  acetate  (CB7630)  in patients  with prostate  cancer.  Br J 
Cancer 90:[ADDRESS_252523], et al: The androgen  axis in recurrent  prostate  
cancer.  Clin Cancer  Res 10:440 -8, 2004  
48. Stigliano  A, Gandini  O, Cerquetti  L, et al: Increased  metastatic  lymph  node 64 and 
CYP17  expression  are associated  with high stage  prostate  cancer.  J Endocrinol  194:55 -61, 2007  
49. Lange  PH, Ercole  CJ, Lightner  DJ, et al: The value  of serum  prostate  specific  antigen  
determinations  before  and after radical  prostatectomy.  J Urol  141:873 -9, 1989  
50. Zincke  H, Oesterling  JE, Blute ML, et al: Long -term (15 years)  results  after radical  
prostatectomy  for clinically  localized  (stage  T2c or lower)  prostate  cancer.  J Urol 152:1850 -7, 1994  
51. Sloan  JA, Loprinzi  CL, Kuross  SA, et al: Randomized  comparison  of four tools  
measuring  overall  quality  of life in patients  with advanced  cancer.  J Clin Oncol 16:3662 -73, 1998  
52. Scher  HI, Eisenberger  M, D'Amico  AV, et  al: Eligibility  and outcomes  reporting  
guidelines  for clinical  trials  for patients  in the state of a rising  prostate -specific  antigen:  recommendations  
from  the Prostate -Specific  Antigen  Working  Group.  J Clin Oncol  22:537 -56, 2004  
53. Ryan  CJ, Smith,  MR, de Bono,  et al: Abiraterone  in metastatic  prostate  cancer  without  
previous  chemotherapy.  N Engl J Med  368: 138-48, 2013  
56 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 APPENDIX A: ECOG PERFORMANCE  STATUS SCALE  
ECOG  Performance  Status  Scale  Karnofsky  Performance  Scale  
Grade  Description  % Description  
 
0 Normal  activity.  Fully  active,  able to 
continue  all predisease  performance  without  
restriction.  100 Normal,  no complaints,  no evidence  of 
disease  
90 Able  to carry  on normal  activity,  minor  
signs  or symptoms  of disease  
 
 
1 Symptoms,  but ambulatory.  Restricted  in 
physically  strenuous  activity  but ambulatory  
and able to carry  out work  of a light or 
sedentary  nature  (eg, light housework,   
office  work).  80 Normal  activity  with effort,  some  signs  or 
symptoms  of disease  
 
70 Cares  for self, unable  to carry  on normal  
activity  or to do active  work  
 
2 In bed < 50% of the time. Ambulatory  and 
capable  of all self-care but unable  to carry  
out any work  activities.  Up and about  more  
than 50% of waking  hours.  [ADDRESS_252524]  needs  
50 Requires  considerable  assistance  and 
frequent  medical  care 
 
3 In bed > 50% of the time. Capable  of only 
limited  self-care,  confined  to bed or chair  
> 50% of waking  hours.  40 Disabled,  requires  special  care and 
assistance  
30 Severely  disabled,  hospi[INVESTIGATOR_44351].  
Death  not imminent.  
 
4 100%  bedridden.  Completely  disabled,  
cannot  carry  on any self-care,  totally  
confined  to bed or chair.  20 Very  sick, hospi[INVESTIGATOR_44351].  Death  
not imminent.  
10 Moribund,  fatal processes  progressing  
rapi[INVESTIGATOR_375]  
5 Dead  0 Dead  
57 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 APPENDIX B: PRO  SURVEY  
 

58 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
  
 

59 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
  
 

Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
60 of 69 12-187 A(15) Protocol.DOCX   
  
 
 

Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
61 of 69 12-187 A(15) Protocol.DOCX   
 APPENDIX C:  JANSSEN SERIOUS ADVERSE EVENT REPORT  FORM  (FOR  
PCCTC)  
 

62 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
  

63 of 69 12-187 A(15) Protocol.DOCX   
 Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017  
 

64 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 
 
65 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
  
 
 
APPENDIX D: PCCTC  SAE REPORT  FORM  FOR  ALL SITES  
 
Please  see the PCCTC  Serious  Adverse  Event Report  Form  
66 of 69 12-187 A(15) Protocol.DOCX  
Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-2017   
 APPENDIX E: GLOSSARY  OF ABBREVIATIONS AND  ACRONYMS  
 
ACTH  adrenocorticotropic  hormone  
ADR  adverse  drug reaction  
ADT  androgen -deprivation  therapy  
AE adverse  event  
ALK -P alkaline  phosphatase  
ALT  alanine  aminotransferase  
ANC  absolute  neutrophil  count  
AR androgen  receptor  
ASAEL  Agent  Specific  Adverse  Event  List 
AST  aspartate  aminotransferase  
AUC  area under  the plasma  concentration -time curve  
BP blood  pressure  
BUN  blood  urea nitrogen  
C02 carbon  dioxide  
CAEPR  Comprehensive  Adverse  Event  and Potential  Risks  
CBC  complete  blood  count  
CFR  Code  of Federal  Regulations  
Cl chloride  
CLIA  Clinical  Laboratory  Improvement  Amendments  
Cr creatinine  
Cmax  maximum  plasma  concentration  
CRDB  Clinical  Research  Database  
CRF  case report  form  
CRPC  castration  resistant  prostate  cancer  
CT computerized  tomography  
CTC  circulating  tumor  cell 
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
CYP  cytochrome  p-450 
dL deciliter  
DHEA  dehydroepi[INVESTIGATOR_211117] -S dehydroepi[INVESTIGATOR_211118]-limiting  toxicity  
DSM  data and safety  monitoring  
ECG  electrocardiogram  
ECOG  Eastern  Cooperative  Oncology  Group  
EKG  electrocardiogram  
EORTC  European  Organisation  for Research  and Treatment  of Cancer  
FDA  Food  and Drug  Administration  
FDG -PET 2-[18F]fluoro -2-deoxyglucose  positron  emitting  tomography  
FDHT  18-fluoro -dehydrotestosterone  
GM-CSF granulocyte -macrophage  colony -stimulating  factor  
67 of 69 12-187 A(15) Protocol.DOCX  Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252525]  
IV intravenous  
K+ potassium  
KLK1  kallikrein  1 
68 of 69 12-187 A(15) Protocol.DOCX  Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252526]  
C Prostate  Cancer  Clinical  Trials  Consortium  
PCWG  Prostate  Cancer  Working  Group  
PET positron  emission  tomography  
PFS progression -free survival  
PI [INVESTIGATOR_211119] (by [CONTACT_1966])  
PQC  product  quality  complaint  
PR partial  response  
PSA prostate -specific  antigen  
PSA- 
DT prostate -specific  antigen  doubling  time 
PSMA  prostate  specific  membrane  antigen  
PT prothrombin  time 
PTT partial  thromboplastin  time 
QOL  quality  of life 
RBC  red blood  cell 
RECIS  
T Response  Evaluation  Criteria  in Solid  Tumors  
RP radical  prostatectomy  
RPC  Research  Program  Coordinator  
RSA  Research  Study  Assistant  
SAE  serious  adverse  event  
SC subcutaneous  
SUV  standardized  uptake  value  

69 of 69 12-187 A(15) Protocol.DOCX  Memorial Sloan  Kettering  Cancer Center  
IRB  Protocol #: 12-187  A(15)  
Approved:  30-JAN-[ADDRESS_252527]  upper  limit  of normal  
WBC  white  blood  cell 
 
